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The U.S. Food and Drug Administration (FDA) uses the FDA Adverse Event Reporting 
System (FAERS) to monitor adverse events resulting from pharmaceutical drug use. 
However, this system has limitations such as not allowing real-time data collection. To 
address these limitations, the FDA launched the Sentinel Initiative in 2008. This 
comparative case study was conducted to describe perceptions of investigating the 
efficacy of the Sentinel Initiative compared with the FAERS. The study was based on the 
theory of preemption as it emphasized the need for efficient means for providing 
unquestionable proof that consumers suffered adverse drug effects. The sample included 
interivews of 20 individuals, who worked closely with the FAERS program and were 
familiar with the Sentinel Initiative. In-depth key-informant interviews had been 
conducted to determine the perceptions of the participants regarding the challenges and 
benefits of the Sentinel Initiative compared with FAERS. To analyze data, content 
analysis was used. The study concluded that the FAERS and Sentinel Initiative provided 
a systematic database, which included health data, that could be used to improve public 
health. Due to the FAERS and Sentinel Initiative, adverse effects of drugs will be 
recognized and the safety of the patients and the public will be prioritized. The findings 
of this study have potential social impact for positive change at the societal level, 
organizational level, and individual level in terms of overall safety of the drugs. Sentinel 
initiative at its present state complements the existing FAERS and leverage its benefits by 
connecting at a grass roots level patients to an organization level as well as stakeholders 
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Chapter 1: Introduction 
The Institute of Medicine (IOM) identified the mitigation of adverse drug events 
(ADEs) and medication errors (MEs) as top national priorities. Budnitz, Lovegrove, 
Shehab, and Richards (2012) found that specific drugs had been reported in 88.3% of 
emergency hospital admissions of older adults caused by adverse drug events. Identified 
drugs tied to emergency hospital admissions were hematologic, endocrine, 
cardiovascular, central nervous system, and anti-infective agents (Budnitz et al., 2012). 
The findings also revealed that 67% of the hospitalizations were due to unintentional 
drug overdoses. In particular, warfarin, insulin, oral antiplatelet agents, and oral 
hypoglycemic agents were found to have accounted for 70% the emergency 
hospitalizations (Budnitz et al., 2012). According to the Institute for Safe Medication 
Practices (2014), when it came to children less than 18 years of age, there were 45,610 
Adverse Drug Reactions (ADRs) reported for 2012. Of these, 64% reported suffering a 
serious injury. Reports of children experiencing ADRs also increased over time, from 
6,320 in 2008 to 11,401 in 2012, increasing at the same rate as for adult patients (Institute 
for Safe Medication Practices, 2014).  
From 1969 to 2012, the Adverse Events Reporting System (AERS) was the 
national database used by the Food and Drug Administration (FDA) to support post-
marketing drug surveillance (FDA, 2012a). The FDA moved from the legacy AERS to 
the FDA Adverse Event Reporting System (FAERS) in 2012. As a result, AERS and 





2012 might refer the surveillance system as AERS while the referenced sources published 
after 2012 might refer it as FAERS, which was the current FDA reporting system.  
The MedWatch report was a reporting system used by patients and health care 
professionals report problems associated with medicines or medical devices. MedWatch 
was very important tool for AERS to obtain safety information on medicinal products 
including medical devices. The same reporting form was used for both patients and health 
care providers, and the reports could be submitted electronically. The reports obtained 
from MedWatch could include information for serious adverse events, product problems, 
and medication errors (Craigle, 2007). In 2011, 874,116 reports were received by the 
FDA through MedWatch, while only 782,733 out of 874,116 were entered into the 
AERS. This was a significant increase from 2003 in which only 370,240 reports were 
received by the FDA through MedWatch (FDA, 2012c).  
Background  
The public saw the FDA as having a big responsibility in ensuring drug safety 
(Gavaza et al., 2012). The FDA, however, relies relied on voluntary reporting of adverse 
events and potential adverse drug reactions because the FDA has had limited resources to 
support active surveillance (Kip et al., 2013). The AERS served as the main surveillance 
database used by the FDA used to determine possible safety-related issues of marketed 
drugs (Wysowski & Swartz, 2005).  
Underreporting, differential reporting, and uneven quality were the common 
limitations of the AERS database; nevertheless, the system-generated reports were often 





product label (Wysowski & Swartz, 2005). Underreporting referred to only a fraction of 
the total number of reportable events being reported (Zhou et al., 2003). Differential 
reporting referred to the fact that more serious events were generally reported as well as 
the events with shorter onset time, such as vaccinations (Zhou et al., 2003). Lastly, 
uneven quality referred to missing or incomplete data on the adverse reaction or reported 
event (Wysowski & Swartz, 2005). On rare occasions, additional regulations up to and 
including market removal had been required by FDA (Wysowski & Swartz, 2005). 
Reports submitted to the FDA reporting system often have insufficient detail 
regarding the consumers who experienced the adverse events or medication errors 
(Berlin, Glasser, & Ellenberg, 2008; Hochberg, Pearson, O’Hara, & Reisinger, 2009). 
The AERS was a system that allowed encoding, managing, analyzing, and reviewing 
adverse event reports from either regulated industry professionals or from the public 
(Berlin et al., 2008; Hochberg et al., 2009). In response to the limitations of the AERS, 
the FDA launched the Sentinel Initiative in 2009, which was designed to provide a 
national electronic-based system to monitor the safety of medical products, including 
drugs, biologics, and medical devices following the mandate of Congress in the FDA 
Amendments Act of 2007 (Platt et al., 2012). The Sentinel Initiative includes two 
components, which were Mini-Sentinel Initiative and the federal partner collaborations 
(Racoosin, Robb, Sherman, & Woodcock, 2012).  
The Mini-Sentinel Initiative, as a part of the pilot phase of the Sentinel Initiative, 
was an electronic program that involved the participation of many different data partners, 





people took and their clinical diagnoses. When the FDA had a query for report 
generation, each data partner would  run the exact same query to generate aggregate 
reports to be sent back to the FDA (Racoosin et al., 2012). To facilitate this process, all 
data partners had a common data model. The second component of the Sentinel Initiative 
was federal partner collaboration among the Center for Medicare and Medicaid Services, 
the Veterans Administration, and the Department of Defense. These federal partners 
administered or ran a population specific health care system (Racoosin et al., 2012). 
Given the limitations of AERS, including the application of the Sentinel program, the 
FDA moved from the legacy AERS to the FDA Adverse Event Reporting System 
(FAERS) in 2012. FAERS contained data encoded into the system since 2004. The data 
were presented at the individual report level with potential duplicates due to factors such 
as follow-up reports on a case.  
There was a need to assess the benefits and challenges of surveillance 
methodology associated with the FDA’s Sentinel Initiative compared to FAERS. The aim 
was to conduct a comparative case study of the current FAERS surveillance system and 
the FDA's Sentinel Initiative to determine the impacts and benefits of the Sentinel 
Initiative in terms of consumer safety. A summary of the attributes of the FAERS and the 









Table 1  
FAERS and Sentinel Descriptions 
 FAERS Sentinel 
Function/Purpose To report the adverse effects of 
drugs and to provide a 
database for these reported 
cases of adverse drug reactions 
 
 
To develop and implement a 
proactive system that would 
complement existing systems 
that the agency had in place to 
track reports of adverse events 
linked to the use of its regulated 
products 
 
Size/Capacity Depend on information 
reported by consumers, Health 
Care Professionals etc. 
Utilized existent large number 
of databases containing safety 
information 
 
Activities Report generation regarding 
errors in medication. 
Information storage on adverse 
events 
 
Support for FDA’s post-
marketing safety surveillance 
program for drug and 
therapeutic biologic products 
 
Query diverse automated health 
care data holders to evaluate 
possible medical product safety 
issues quickly and securely 
 
 
Limitations There was no certainty that the 
reported event was actually 
due to the product (FDA did 
not require a causal 
relationship between a product 
and event). 
 
The quality of reporting was 
dependent on the quality of the 
reports. 
 
Reports did not always contain 
enough detail to properly 
evaluate an event. FDA did not 
receive reports for every 
adverse events  
There were some data that might 
be missing in the database to 
facilitate activities other than 
analysis of errors in medication 







Problem Statement  
The current FDA consumer safety surveillance system used FAERS for the 
reporting of adverse events involving pharmaceutical drugs (FDA, 2012a; Powers & 
Cook, 2012;). The FAERS used a database that was designed to assist the FDA and its 
partners to monitor postmarketing safety of approved drugs and other biologic products 
(Powers & Cook, 2012). The FAERS had limitations including not allowing real time 
data collection (FDA, 2012a). In response to these limitations, the FDA launched the 
Sentinel Initiative in 2008. However, there is a dearth of literature regarding the impact of 
Sentinel Initiative compared to the FAERS. There is a need to assess the benefits and 
challenges associated with the FDA’s Sentinel Initiative compared to the current FAERS 
surveillance methodology. 
This comparative case study was conducted to assess the impact of two systems: 
the Sentinel Initiative and FAERS. According to the FDA (2012a), the FAERS had two 
functions: (a) a system for reporting the adverse effects of drugs, and (b) a database for 
these reported cases of ADRs (FDA, 2012a).  As for the Sentinel Initiative, the function 
was to build and implement a national electronic system for monitoring the safety of 
FDA-approved drugs and other medical products (FDA, 2012d). 
The FAERS and the Sentinel program were both ADR reporting systems. The 
Sentinel system was developed and implemented as an aid to the existing FAERS. The 
FAERS did not make use of data at the point of care, which referred to the precise time or 
location that a drug was used or consumed by the market members (Gottlieb, 2005).  





diverse automated healthcare data holders—like electronic health record systems, 
administrative and insurance claims databases, and registries—to evaluate possible 
medical product safety issues quickly and securely” (para. 2). 
Purpose of the Study 
The purpose of the comparative case study of the FAERS surveillance system and 
the FDA’s Sentinel Initiative was to determine the benefits and consequences of the 
Sentinel Initiative in terms of drug consumer safety. This qualitative study focused on the 
perceptions of individuals who had worked closely with FAERS program and were aware 
of the Sentinel Initiative. Key informants were interviewed who worked with FAERS 
andwere familiar with the Sentinel Initiative to understand their perceptions of the 
differences between these two programs. 
Currently, the reporting system utilized by the FAERS is voluntary and quarterly 
(Powers & Cook, 2012). Instead of depending on point of care data collection, Sentinel 
Initiative could access multiple existing data systems such as electronic health record 
systems and medical claims databases (Platt et al., 2009). No quantification of data was 
carried out to compare information on the two programs. Instead, the perceptions of key 
informants were used to describe any differences between the two programs.  
Research Questions  
In conducting a comparative case study on the perceptions of the two systems that 
the FDA used to detect ADRs, these following research questions were used: 
Research Question 1: What are the prospective benefits of the FDA’s Sentinel 





Research Question 2: What are the challenges and negative impacts of the FDA’s 
Sentinel Initiative as compared with the FAERS surveillance methodology? 
Research Question 3: What are the lessons learned that can enhance the scope of 
the Sentinel Initiative?  
Theoretical Framework 
The theory of preemption was used to frame the study. The theory of preemption 
assumes the importance of using information to make sound judgments regarding issues 
or activities of national importance, such as prescription drug-related regulations or 
required uniform federal regulation, which cannot be provided by states (Deftos, 2008; 
Glantz & Annas, 2008). The theory of preemption is used to analyze data from ADRs and 
cases to address the damages experienced by affected consumers (Valoir & Ghosh, 
2011).  
The theory of preemption might shield drug manufacturers from certain liabilities 
when consumers experience adverse effects from their products (Curtin & Relkin, 2007). 
Court rulings and federal decisions had shown support for the protection of drug 
manufacturers who faced allegations of adverse drug effects from their consumers 
(Curtin & Relkin, 2007). Preemption prevented state courts from assessing the safety and 
efficacy of a drug when it came to a personal injury products liability lawsuit, thereby 
giving drug manufacturers the ability to avoid litigation even if the patient who suffered 






The theory of preemption was important in framing the study as it emphasized the 
need for efficient means for providing unquestionable proof that consumers suffered 
adverse drug effects. Because this studyfocused on the comparison between two 
surveillance and reporting systems with the goal of improving drug safety, the theory of 
preemption was the most appropriate theoretical framework for the study. Under the 
theory, the FDA required current, accurate, and actionable information to ensure 
consumer safety, especially in detecting uncommon cases of product exposures (Platt et 
al., 2009). 
Nature of the Study  
This comparative case study design waswas qualitative in nature. Qualitative 
methodology was appropriate for this study because qualitative studies are used to 
explore a phenomenon within its natural environment (Yin, 2011). Moreover, a 
comparative case study design was appropriate because the aim was to explore the 
differences and similarities between two cases, (a) use of FAERS and (b) use of Sentinel 
Initiative, based on the perspectives of participants (Yin, 2011). In-depth key-informant 
interviews had been conducted to determine the perceptions of the participants regarding 
the challenges and benefits of the Sentinel Initiative compared with FAERS. The data 
analysis technique used was content analysis. Krippendorff (2004) stated that content 
analysis involved the development of thematic categories and themes from qualitative 






Key informants included drug company safety professionals who had self-
reported knowledge or expertise in assessing consumer impact. The participants were 
selected from various departments within pharmaceutical companies located in the 
United States. The participants were subject matter experts in the field of 
pharmacovigilance. Sampling involved participants at different levels from different 
therapeutic departments such as pain and inflammation, cardiovascular, and psychiatric 
and mental health.  
Definitions 
Adverse drug reaction (ADR): “Any response to a drug, which is noxious, 
unintended and occurs at doses normally used for prophylaxis, diagnosis or therapy” (van 
Grootheest & Richesson, 2012, p. 368).  
Pharmacovigilance: “The science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects or any other drug-related 
problems” (World Health Organization [WHO], 2014, para. 1).  
FDA Adverse Event Reporting System (FAERS): An information database system 
which was acted as the post-market monitoring system for the FDA. FAERS used 
historical data or information to supervise new adverse events and medication errors from 
drug and therapeutic biologic products (FAERS, 2012a). 
FDA Sentinel Initiative: A national electronic system that allowed the FDA to 






 There were several assumptions in the study. The first was that the participants 
would answer each question in the interview as truthfully and accurately as possible. This 
was a necessary assumption because this could not be controlled fully; however, before 
the interview started, the participants were reminded of this. The second assumption was 
that the two programs were comparable, especially because they dealt with the same 
issues, specifically adverse event reporting. The third assumption was that the both 
programs had benefits and challenges to determine room for improvement as part of the 
implications of the study findings. 
Scope and Delimitations  
The perceptions of the participants were gathered regarding the challenges and 
benefits of the Sentinel Initiative compared with the FAERS. Interviews were conducted 
with participants who met the inclusion criteria: (a) safety professionals from drug 
companies and (b) had self-reported knowledge or expertise in assessing consumer 
impact. 
Limitations 
There were many limitations in this study such as sample size, researcher bias, 
and data collection bias. Each limitation had an impact on this study and every effort was 
made to control the effects of the limitations. One limitation was researcher bias. I have 
extensive knowledge of Adverse Drug Reactions (ADRs) and pharmacovigilance 
systems. To mitigate this bias, data collected was examined during participant interviews 





consistent with the actual interpretations intended by the participants.  This limitation 
might have had an effect on the interview questions used for data collection. Recognizing 
this, the questions were written without bias to allow the participants to use their 
experiences and knowledge to answer the questions. 
Another limitation was the possibility of not obtaining enough participants. Key 
informants included drug company safety professionals who had self-reported knowledge 
or expertise in assessing consumer impact. Another factor that might have resulted in 
inadequate results was poorly developed interview questions. The interview guide must 
be developed properly to be open ended yet specific enough to avoid confusion. To avoid 
this pitfall, proper considerations were given in developing the interview guide. Another 
limitation was sample size selection. The study was limited to sample 20 participants 
with the consideration of data saturation. The required sample size for qualitative studies 
was based on the point of data saturation (Mason, 2010). 
Social Significance 
 This study definitely may have potential to increase awareness of advantages and 
disadvantages of the FAERS and the Sentinel Initiative programs. It was expected that 
the data would provide information regarding the effectiveness of the FAERS and the 
Sentinel Initiative. This study may increase public knowledge of the reporting systems 
used by the FDA to control ADRs. The lessons learned from this study may be used to 
support the FDA’s efforts to improve reporting systems’ effectiveness to detect ADRs. 
This current study may also add to the research base regarding pharmacovigilance 





FAERS and the Sentinel systems may serve as basis for further improvements to the 
programs. As a result, health and quality of life may be improved because the challenges 
of the programs on ADR generation may be identified for ease of addressing them. It 
could support the FDA’s efforts to improve reporting systems effectiveness to detect 
ADRs.  
Summary 
 The occurrence of ADRs in the United States had increased in the past decade 
(Yadav, 2009). ADRs were costly and could have a negative impact on public health 
programs that detect ADRs (Yadav, 2009). Furthermore, ADRs were among the leading 
causes of death in many countries, including the United States. According to Keating and 
Millman (2014), from 2004 to 2012 men and women reported 60,000 deaths. Despite the 
similarities in their numbers, death was the number one ADR among men, while it was 
the ninth among women. Pharmacovigilance systems were used to detect and prevent 
ADRs. The purpose of this qualitative comparative case study was to compare two ADR 
reporting systems to determine whether one was more effective than the other. This 
investigation might lead to a better understanding of the effectiveness of the ADR 
reporting systems and assist the FDA with improving ADR surveillance and reporting. 





Chapter 2: Literature Review 
The purpose of this comparative case study of the US Food and Drug 
Administration (FDA) Adverse Events Reporting System (FAERS) surveillance system 
and the FDA’s Sentinel Initiative was to determine the benefits and consequences of the 
Sentinel Initiative in terms of drug consumer’s safety. Instead of depending on point-of-
care data collection like the FAERS surveillance system, the Sentinel Initiative accessed 
multiple existing data systems, such as electronic health record systems and medical 
claims databases (Platt et al., 2012). Perceptions of the perceived challenges and benefits 
of FAERS and Sentinel Initiative were gathered through key informant interviews with 
individuals who worked with FAERS and were familiar with the Sentinel Initiative. Robb 
et al. (2012) described the mission of the FDA as providing health protection to the 
public. To do this, the regulatory body ensured the safety, efficacy, and quality of the 
human drugs. Aside from human drugs, the FDA also regulated the quality and safety of 
biologic products, medical devices, and more (Robb et al., 2012).  
For years, the regulating body was dependent mostly on spontaneous reporting 
systems to complete its task of monitoring post-market safety. The FDA relied heavily on 
the public, practitioners, and consumers to voluntarily report adverse drug effects, errors, 
and other quality problems either to the FDA or directly to the drug companies. Although 
manufacturers were mandated by law to report to the FDA when adverse events were 
reported to them, the FDA still required active public participation in reporting such 
occurrences. Naturally, these spontaneous reporting approaches for ADRs had their 





One of the weaknesses of such an approach was the underreporting of adverse 
events and incomplete information on the reports submitted to the FDA. Moreover, even 
though these systems were strong for developing hypotheses regarding possible product-
associated adverse events, the number of events being reported did not accurately 
represent the actual number of cases of ADRs (Alvarez-Requejo et al., 1998). 
Aggravating this was the lack of exposure data, which served as a barrier for accurately 
calculating adverse event rates. The FDA was aware of these limitations and continued to 
strive for stronger post-market safety monitoring. The literature review begins with the 
history of the FDA and its role in ensuring drug safety, followed by studies covering 
ADR surveillance using FAERS and the Sentinel Initiative.  
Literature Search 
To conduct the literature review, relevant studies were searched that contributed 
to the development of the research topic for this study. The databases used for this study 
were EBSCOHost, PsychArticles, ProQuest, and ScienceDirect. The key words used 
included adverse events reporting system, surveillance system, FAERS, FDA Sentinel 
Initiative, pharmacovigilance, and ADR.  The search for articles was focused on works 
published from 2009 to 2014, with exceptions for seminal works that were essential to 
the development of the study. The key words were used in the database search as 
individual and combined terms to identify appropriate articles for this literature review. 
Theoretical Framework 
The theory  used to frame this study was the theory of preemption, which is based 





regulations, or common-law damage actions. When it comes to preempting common-law 
damage actions, the plaintiffs cannot sue for damages regarding injuries caused by a 
product. Preemption is considered an affirmative action, which means the burden of proof 
lies with the defendant to adhere to the preemptive effect of the federal law (Shniderman, 
n.d).  
Because the theory of preemption involves the use of data to make market-based 
decisions regarding drug safety (Gostin, 2011), the theory of preemption was the most 
appropriate theoretical framework for the study, which focused on the comparison 
between two surveillance and reporting systems with the goal of improving drug safety. 
The theory of preemption is used with quantitative data from adverse drug effect reports 
and cases to address the damages experienced by affected consumers (Gostin, 2011). 
According to Gostin (2011), the two cornerstones of the preemption theory are 
Congress’s intent to be the ultimate touchstone and the “strong presumption against 
preemption when the state exercises its historic police powers” (p. 11). Because of this 
doctrine, even though the FDA was viewed as ineffective and even if ineffective drugs 
and devices were being marketed, consumers had limited recourse to be fairly 
compensated for their injuries (Gostin, 2011). 
The theory of preemption shields drug manufacturers from certain liabilities when 
consumers experience adverse effects from their products (Shniderman, n.d.). Preemption 
is often the position taken when an injury to a patient or plaintiff is reportedly caused by 
prescription drugs (Shniderman, n.d.). Under this theory, the approval process is the 





the agency’s capabilities in regulating risk information for prescription drugs. Under 
preemption, the FDA is considered to have the requisite expertise to deal with issues of 
safety and efficacy of prescription drugs. The FDA argued that approval of drugs’ label 
demonstrated the agency’s definitive judgment of certain risks and this judgment should 
be protected from second-guessing (Kessler & Vladeck, 2008). Recent court rulings and 
federal decisions had shown much support for the protection of drug manufacturing 
companies who faced allegations of adverse drug effects from their consumers (Curtin & 
Relkin, 2007). This theory was important in framing and shaping the significance of this 
study as it emphasized the need for efficient means of providing unquestionable proof 
that consumers suffer adverse drug effects.  
Evolution of FDA and Drug Safety 
History of Drug Safety  
Ensuring the safety of the food supply and safeguarding the public from the 
practice and effects of adulteration and misleading marketing was probably the earliest 
regulatory task undertaken by ancient governments, and when the Roman civil law was 
established, there were already complex rules addressing these issues (Borchers, Hagie, 
Keen, & Gershwin, 2007). In the United States, such regulatory activities were originally 
under the auspices of the state. No federal food laws were designed until the 1880s, when 
Congress started to enact statutes regulating individual food items, such as the laws 
banning the importation of adulterated tea, limiting the manufacture of oleomargarine, 





The history of federal drug laws could be observed to go back further. In 1813, 
Congress put into place the Vaccine Act, which was the first statute facilitating the 
regulation of adulterated drugs. Afterward, a more general federal law on drug 
adulteration was called for. The U.S. -Mexican war had just ended, and members of 
Congress were convinced that adulterated and decayed foods and drugs explained why 
there was a high mortality of soldiers in this war (Borchers et al., 2007). Although many 
soldiers of the U.S.- -Mexican war died because of the infectious diseases and general 
inadequacy of medical treatment, Congress was convinced that adulterated and inferior 
drugs played a large role in the high mortality rate of the soldiers, and this conviction led 
to the passage of the Drug Importation Act of 1848. The Treasury Department acquired 
the responsibility of enforcement but found it difficult over time. In addition, one 
weakness of the law was that it only addressed the importation of adulterated drugs and 
not their manufacture and sale within the United States (Borchers et al., 2007). 
The Division of Chemistry investigations began in the mid18th century, and 
Wiley, who became chief chemist in 1883, greatly influenced the U.S. government to 
take on the adulteration and misbranding of foods and drugs. Wiley published a 10-part 
study in 1887 called “Foods and Food Adulterants,” and in 1902 conducted famous 
poison squad experiments in which volunteers would take food additives to see their 
reaction (Borchers et al., 2007). Wiley then convinced the General Federation of 
Women’s Clubs, consumer groups, trade associations, professional groups, and state food 
and drug officials to stand behind a federal law prohibiting adulteration and misbranding 





Role of FDA in Drug Safety 
When the 19th Century ended, many infectious diseases were discovered. 
Antitoxins and vaccines could treat and prevent the diseases. However, in October and 
November 1901, 13 children died because of inoculation with a diphtheria antitoxin 
contaminated with tetanus bacillus (Borchers et al., 2007). As an immediate response, 
Congress and President Theodore Roosevelt passed the Biologics Control Act of 1902 
mandating that establishments wanting to produce and sell market vaccines and 
antitoxins should have the required licenses. This was facilitated by the Public Health and 
Marine Hospital Service, now known as the U.S. Public Health Service (Borchers et al., 
2007). 
The Wiley Act, or the Pure Food and Drugs Act of 1906, banned interstate 
commerce in adulterated foods, drinks, and drugs. The Act mandated that producers 
should put labels on their products that indicated whether the medication consisted of 
“alcohol, opium, cocaine, morphine, chloroform, marijuana, acetanilide, chloral hydrate, 
and in what amount” (Borchers et al., 2007, p. 6). However, while the Wiley Act 
prohibited false and misleading statements on the product or its ingredients, the Act did 
not consider advertising material as part of the label. This created vagueness of the Act. 
Nevertheless, the Act was commended for establishing the role of the federal government 
as the protector of consumers. Moreover, the Wiley Act created the first federal 
regulatory agency that would later become the FDA. Wiley, who was the head of the 
Bureau of Chemistry, took on the role of the first chief administrator of this new agency 





there was insufficient budget and partly because the Bureau of Chemistry had to bring 
each company to court to prove adulteration, mislabeling, or other violations. While the 
Act put forward what was fraudulent (misleading the consumer), it was not easy to prove 
fraudulence took place (Borchers et al., 2007).  
The FDA petitioned for changes in laws, which “legally mandated quality and 
identity standards for foods, the prohibition of false therapeutic claims for drugs, 
coverage of cosmetics and medical devices, clarification of the FDA’s right to conduct 
factory inspections and control of product advertising, among other items” (Hickmann, 
2003, p. 11). Together, the FDA and a new generation of journalists and consumer 
organizations banded together in attempts to influence the passing of this new legislation 
through a reluctant Congress (Hickmann, 2003, p. 11). Unfortunately, it was another 
therapeutic disaster that propelled the legislation through Congress, for in 1937, a 
Tennessee drug company marketed elixir sulfanilamide, which was popular in the 
pediatric population. This sulfa drug contained a chemical found in antifreeze; as a result 
of the substance, more than 100 people died, most of them were children (Hickmann, 
2003, p. 183). 
Because of the Tennessee drug company tragedy, Congress enacted the Food, 
Drug, and Cosmetic Act on June 25, 1938. This Act regulated cosmetic and medical 
device and requirement of label medication with usage instructions. In addition, pre-
market approval from the FDA was another big initiative that enhanced safety and 
efficacy of drugs. Another positive change resulted in the area of food packages, food 





enforce other safety requirements per the agency’s guidelines (FDA, 2012d). In addition, 
in 1938, another therapeutic disaster spawned the creation of the Kefauver-Harris 
Amendments. Thalidomide, a sedative that was used outside of the United States, had 
caused thousands of deformed newborns. The Kefauver-Harris Amendments also 
provided for drug efficacy and safety evaluation by the FDA before marketing, stricter 
regulation of drug trials, improved drug manufacturing practices, and the empowerment 
of the FDA to assess drug company production and control records (FDA, 2009). 
In 1960, more than $1 billion dollars of medical devices were shipped by more 
than 1,000 manufacturers. In the early 1970s, approximately 10,000 injuries were 
documented by government because of usage of these medical devices. However, after 
causing more than 200-second trimester septic abortions and 11 maternal deaths, the 
Dalkon Shield intrauterine device was withdrawn from the market. In response to this and 
other events, Congress enacted the Medical Amendments of 1976 to ensure the FDA’s 
ability to maintain safety and effectiveness of medical devices entering the market 
(Maisel, 2004). The legislation was founded on the idea that the degree of device 
regulation should correspond to the degree of risk one could be exposed to by using the 
device. As a result, the FDA pre-market evaluation and approval, carried out by the 
Center for Devices and Radiologic Health, was largely determined by what the device 
was and the level of risk perceived to the patient’s health (Maisel, 2004).  
The legislation included three regulatory classes. This new legislation divided 
medical devices into three tiers based on the risk posed by the device. Class 1 (low risk 





such as stethoscopes and tongue blades. Because they posed minimal risk, their safety 
and effectiveness were maintained through general controls only (Maisel, 2004). Class 2 
(moderate risk devices) medical devices functioned under FDA performance standards 
and consisted of such products as computed tomography scanners and gastroenterology 
endoscopes. Class 2 devices were regulated by making sure they met or even exceeded 
specific predefined product performance standards (Maisel, 2004). Class 3 devices 
(higher risk devices) such as pacemakers and silicone breast implants were the most 
heavily regulated and require the FDA’s premarket approval (Maisel, 2004). The safety 
and effectiveness of Class 3 devices were maintained by carrying out a comprehensive 
and thorough pre-market evaluation and approval process (Maisel, 2004).  
According to Maisel (2004), for devices to be stamped with FDA approval and 
enter the United States market, manufacturers should first show that the device was safe 
by proving the possible risks were minimal or the benefits would outweigh the risks. 
Manufacturers should also show that the device was effective by proving that it could do 
what it committed to do for users. Manufacturers must show data that supports their 
safety and effectiveness claims, which might include verification and validation studies, 
observational studies, randomized clinical trials, manufacturing tests, and statistical risk 
analyses (Maisel, 2004). The manufacturer would choose evidence based on what was 
required by the FDA to determine safety and effectiveness, which was largely dependent 
on the type of device and what it had promised to users. The perceived risk of the user’s 
well-being was also a factor determining what evidence the FDA would ask for. For 





condition for which no alternative existed, the FDA might consider the device as having a 
higher acceptable risk compared to devices that were manufactured with the intention of 
treating a benign condition (Maisel, 2004). Congress called for the FDA to use the “least 
burdensome approach,” which meant the FDA should only require manufacturers to 
provide the necessary data for them to prove the safety and effectiveness of their devices 
(Maisel, 2004).  
 Under this new regulation, devices were approved by the FDA and entered the 
market in either of the two ways: first, by showing substantial equivalence to an already 
approved and legally marketed device and second, by providing data as evidence of 
safety and effectiveness through the Pre-market Approval Application (Maisel, 2004). 
Devices that posed only minimal risk were exempted from intense scrutiny and might 
only need to be subjected to registration and listing with the FDA. Others might only 
require evidence that they had passed compliance with manufacturing guidelines. The 
FDA put forward Guidance documents, which summarized what manufacturers need to 
provide and show before their devices were approved (Maisel, 2004). According to 
Borchers et al. (2007), the evolution of FDA could be characterized as a series of “crisis-
legislation-adaptation cycles.” It was always a crisis that triggered a legislation to be 
made and followed by the implementation or adoption of the FDA legislation. 
Pharmacovigilance 
Pharmacovigilance referred to science and activities linked to detection, 
assessment, understanding and prevention of adverse effects or any other drug-related 





exchanging, accumulating, analyzing, interpretation and sharing of data regarding the 
experiences of patients who had used a specific drug or certain therapeutic agent. 
Pharmacovigilance played an important role in ensuring drug safety and the activities 
associated with it had become increasingly scrutinized by the drug industry (van 
Grootheest & Richesson, 2012, p. 368). According to van Grootheest and Richesson 
(2012), pharmacovigilance and drug safety monitoring activities could shape clinical 
research practices significantly. Most pharmacovigilance and population monitoring 
activities were also clinical research studies themselves, so that they could also affect 
research and development activities. The findings of pharmacovigilance and drug safety 
monitoring activities could led to improved decisions by treatment agent manufacturers 
as well as improved future trials (van Grootheest & Richesson, 2012).  
If there were no systematic detection and assessment practices in place that could 
deal with adverse drug effects, thousands of individuals might suffer from side effects of 
the drugs they used before a clinician could be subjected to public investigation and 
action (van Grootheest & Richesson, 2012). An adverse event was a clinical event, sign 
or symptom that deviated from the wanted results. No concept of causality had been 
asserted with adverse events. On the other hand, an ADR implied causality or a causal 
relationship between the drug and the event. One was the probable cause and one was the 
effect. If an ADR were suspected, then trials and tests would have to be carried out in 
order to confirm or refute the suspicion. Before tests were carried out, careful and 





The decision to ban thalidomide from the market was the result of actively 
collecting data and cases of adverse reactions to the drug. This case also propelled the 
FDA to start a systematic collection of ADR reports, mainly through the Hospital 
Reporting Program. The case also led to different countries establishing policies that 
would regulate new drugs, which composed of new rules and regulations that new drugs 
have to meet before receiving marketing authorization. Moreover, marketing 
authorization holders were commissioned to form a system focused on post-marketing 
surveillance so that ADRs could be detected as early as possible and prevented a similar 
case as the thalidomide from taking place (van Grootheest & Richesson, 2012). In 1968, 
10 countries that supported the spontaneous reporting system of ADRs collaborated to 
establish International Drug Monitoring (Lindquist, 2003). In 1971, the 20th World 
Health Assembly proposed the foundations for the WHO International Drug Monitoring 
programme (van Grootheest & Richesson, 2012). In 1972, a report was written to serve 
as the foundation for the international system of national centers working together under 
the WHO programme (van Grootheest & Richesson, 2012). 
Even though these sophisticated programs and models had changed through time, 
the motivation and main strategies behind pharmacovigilance had not changed. The main 
motivation to carry out pharmacovigilance was still to ensure public safety and the main 
strategy was still population monitoring (van Grootheest & Richesson, 2012). In addition, 
the overall goal of pharmacovigilance was to balance the risks associated with a drug to 
the benefits that could be gained from it. Pharmacovigilance sought to balance the risk-





level of risks and these risks were not equally distributed across the population. Some 
groups were more likely to suffer from ADRs compared to others (van Grootheest & 
Richesson, 2012). Pharmacovigilance did not deny the possibility of risks associated with 
certain drugs and more importantly; it was cognizant that individual variations that could 
affect the course of a disease should be taken into consideration. Individual variations 
also dictated the preferences of treatment options and an individual’s tolerance of side 
effects (van Grootheest & Richesson, 2012). 
According to Raine (2012), harmful effects from drugs should be monitored, as 
they could be deadly and costly to the healthcare sector. The costs were high in 
developed countries, but could be even greater in developing countries (Raine, 2012). For 
these countries, even if only a few patients suffer real harm from ADR, these incidents 
might cause significantly negative consequences on the credibility and success of 
important public health programs (Raine, 2012). 
Such situations highlighted the need for pharmacovigilance, which was the 
science and method of detection, assessment, and comprehension of adverse drug related 
problems. To enhance pharmacovigilance strategies, the WHO claimed that more 
emphasis must be given to the planning and implementing of ADR surveillance systems 
(Raine, 2012).  
Methods in Pharmacovigilance 
There were various methods used in detecting new ADR, categorized into pre-
marketing and post-marketing studies. The primary method of gathering information 





Grootheest & Richesson, 2012). Double-blind randomized controlled trials comprised the 
most comprehensive method of determining the possible cause-effect relationship 
between a treatment agent and a specific outcome. This study was not completely 
effective in determining the safety of a drug, especially because only limited number of 
patients participates. This made it impossible to determine rare ADRs as a result. 
Moreover, the short period on which clinical trials were carried out made it challenging 
to identify ADRs with a long latency (van Grootheest & Richesson, 2012). The 
effectiveness of clinical trials was also questionable when the population in which a drug 
was tested was taken into account (van Grootheest & Richesson, 2012). 
Specifically, the problem lied with the fact that characteristics of the persons to 
which this drug was tested would not always correspond to the characteristics of the 
people who would actually use the drug. This made it harder to generalize findings 
gathered from clinical trials to the population at large. This could be especially observed 
among the elderly, women and with disabilities (van Grootheest & Richesson, 2012). 
Rare ADRs therefore could be detected more with post-marketing studies rather that tests 
carried out before the drugs were carried out. Careful monitoring of the drug and its 
effects after they had been released to the market was necessary (van Grootheest & 
Richesson, 2012). 
Post-marketing studies could be either descriptive or analytical (van Grootheest & 
Richesson, 2012). The former type of post-marketing studies could lead to hypotheses 
that would describe how events occurred in relation to the toxicity of the drug as well as 





marketing surveillance, the hypotheses generated from the descriptive studies served as 
the starting points of analytical studies (van Grootheest & Richesson, 2012). Spontaneous 
reporting as well as intensive monitoring were the two dominant types of descriptive 
studies. On the other hand, there were different methods to carry out analytical studies 
such as case-control studies, cohort studies, clinical trials and more others. Most of these 
studies could only be carried out if there were already reliable data available (van 
Grootheest & Richesson, 2012). 
A spontaneous reporting system (SRS) such as FAERS was considered the main 
method of gathering post-marketing information regarding the safety of drugs. SRS were 
designed to detect signals of new, rare, as well as significant ADRs as early as possible. 
By having an organized spontaneous reporting system, parents, physicians, and the 
patients would all have the opportunity to reported ADRs as early as the day they had 
suspicions to a pharmacovigilance center (van Grootheest & Richesson, 2012). 
The pharmaceutical companies also made use of SRS to research their own drugs. 
The SRS enabled them to monitor their drugs at their whole life cycles for minimal costs 
(van Grootheest & Richesson, 2012). However, SRS were critiqued for their selective 
and underreporting. According to a study, where the researchers evaluated the magnitude 
of underreporting, more than 94% of ADRs were not being reported. Because of this 
underreporting, FDA, the pharmaceutical companies, and the public had a misconception 
that the specific drug was safe. On the other hand, selected reporting of risks could lead 






Still, even though criticisms abound, it had proven its value throughout the years. 
From 1999 to 2011, 11 drugs were withdrawn from the American and British markets, 
which were two of the globally prominent markets. This showed how valuable SRS was. 
Among the 11 drugs, eight were removed because of the findings shaped by and because 
of spontaneous reporting (van Grootheest & Richesson, 2012). The WHO gave 
importance to spontaneous reporting systems as an important part of pharmacovigilance, 
given their capacity to reduce the risk of drug-related problems (Raine, 2007). According 
to Herdeiro et al. (2012), spontaneous report methods were the most dominant form of 
reporting ADRs. However, this method was prone to physicians’ underreporting 
(Herdeiro et al., 2012).  
To address this concern, Herdeiro et al. (2012) conducted an experiment to see if 
particular interventions could help increase instances of physicians reporting ADRs. 
Herdeiro et al. (2012) compared the results of workshops and over-the-phone interview 
interventions designed to enhance the quantity and relevance of ADR reporting by 
physicians. Herdeiro et al. (2012) performed a cluster-randomized controlled trial, 
wherein 6,579 physicians from northern Portugal were gathered to participate in 2008. 
After conducting randomization, Herdeiro et al. (2012) put 1,034 physicians in a group 
conducting telephone-interview interventions, and 438 in a group under the category of 
workshop intervention. The remaining physicians were categorized as the control group 
(Herdeiro et al., 2012).  
At the workshop, a real clinical case was demonstrated and the physicians were 





over-the-phone intervention, the physicians answered questions pertaining to whether 
they had ever suspected ADRs and whether they suffered any challenges when it came to 
reporting these (Herdeiro et al., 2012). They were also asked whether they could recall 
the methods for reporting ADRs and whether they found it important that they, as 
physicians, had a hand in the reporting process, faced difficulties in reporting, propose 
different method of reporting, or value reporting adverse events (Herdeiro et al., 2012).  
Statistical analyses of data from all groups revealed that the workshop 
intervention had the ability to increase spontaneous ADR reporting rates by an average of 
400% up to 20 months after intervention (Herdeiro et al., 2012). On the other hand, 
telephone interventions were not found as efficient or effective. They led to no significant 
increase in spontaneous ADR reporting in comparison to the control group (Herdeiro et 
al., 2012). Still, for the first four months, telephone interventions did increase 
spontaneous reporting (Herdeiro et al., 2012). Based on the study of Herdeiro et al. 
(2012), it could be concluded that interventions in general could improve spontaneous 
ADR reporting. However, workshops were better at increasing both the quantity and 
relevance of spontaneous ADR reporting for a longer time. 
Lorimer, Cox, and Langford (2012) analyzed the influence of ADRs on patients 
and their views on reporting. The researchers interviewed the patients who experienced 
an ADR and were admitted in an inner city hospital. The researchers found that most of 
the patients were afraid of being admitted to the hospital. More than anyone, they 
expected the healthcare professional to prescribe the medication that would not cause 





read the patient information leaflet. As such, when an adverse reaction occurred after 
taking a medication, few of them associated the adverse effects with the medication. 
Some of them, however, received false reassurance that the drugs were not behind the 
adverse event or the illness. These factors led to additional barriers to accurate reporting 
of adverse reactions. A majority of the patients believed that adverse drug reporting 
should not be their responsibility (Lorimer et al., 2012). 
From the 1970’s to the 1980’s, intensive monitoring had emerged as another 
descriptive method of identifying ADRs in New Zealand and the UK, which was called 
Prescription Event Monitoring. Under this method, prescription data was utilized to 
determine who the users of a specific drug were. The prescriber was questioned on any 
incidences of adverse event that took place when the drug had been in use. The data 
gathered from the prescriber were considered as new signals (van Grootheest & 
Richesson, 2012). The benefits of intensive monitoring were many. First, the findings of 
this method were not affected by the kind of selection and exclusion criteria the same 
very clinical trials were. Moreover, because identification of ADRs was done through 
monitoring, this could result into the identification of signals for events that were not 
initially perceived as ADRs of the drug being monitored. In addition, this method could 
lead to the estimation of how frequent the ADRs of a certain drug took place, thereby 
made it possible to quantify the risks of ADRs (van Grootheest & Richesson, 2012). 
When a new drug was approved, its safety could only be ascertained through the 
responses of the several thousand people who took it during clinical trials. However, once 





introduction, the number of people who were exposed to the medication and its effects 
might rise significantly into millions, especially if the drug manufacturer practices 
rigorous and aggressive marketing and advertising through television, print and more 
others (Okie, 2005). If the drug had dangerous and yet unusual side effect, for instance, 
liver failure that was only suffered by one in 1000 patients, that effect would normally be 
acknowledged and determined only after the medication had already been taken by 
millions of users. In addition, if the drug increases the occurrence of a common 
condition, for instance, myocardial infarction, this risk could only be recognized after a 
million of people had used the drug as well (Okie, 2005). Almost 50% of the drugs that 
were introduced to the market had serious adverse effects that were only recognized once 
they were already approved (Okie, 2005). What was worse that most Americans were 
usually the test population. Because of the quicker review of product applications 
conducted by the FDA, at least 60% of new drugs were always approved first in the 
United States, unlike decades ago, when drugs were often approved in other countries 
(Okie, 2005).  
This shift led to a parallel increase in the attention given by experts, lawmakers, 
consumer advocates and federal officials to drug safety. They call for better ways of 
monitoring the effects and safety of already approved drugs (Okie, 2005). The fact that 
more Americans were taking prescription drugs served to make the calls more urgent. In 
2004, pharmacists had filled 3.1 billion prescriptions, around 60% of which were more 
than 10 years earlier. Reports to the FDA of drug-related adverse reactions had also 





number a decade ago (Okie, 2005). These figures were alarming considering the agency's 
current surveillance system was passive, depending on the diligence of drug companies 
only, as well as the reports of healthcare providers and consumers (Okie, 2005). 
According to policy experts, a new system should be in place to obtain 
observational data on significant numbers of people who were vulnerable to medications 
being introduced to the market (Okie, 2005). The information might be collected from 
databases as they were increasingly accessible through many managed-care networks and 
other providers shifted to the use of electronic medical records (Okie, 2005). According 
to Kuehn (2012), IOM called for the FDA to be more aggressive and proactive in 
responding to the safety concerns that emerged after a drug had been introduced to the 
market. 
Based on the study of Dart (2009), the main purpose of post-marketing 
surveillance was for the FDA to provide accurate information on the risks associated with 
a drug. Drugs that affect the central nervous system comprised a group of products that 
should be surveyed because they were usually used inappropriately either by misusing 
them, abusing them or diverting them (Dart, 2009). Examples of these medications were 
opioid analgesics, stimulants, sedative-hypnotics, muscle relaxants, anticonvulsants and 
more other drugs (Dart, 2009). The adverse events associated with these drugs were 
complex to monitor because the perpetrator was usually determined to hide the misuse, 
abuse and diversion of the drug (Dart, 2009). As such, an effective post-marketing 
surveillance system for prescription drug would be one that provides specific information 





memo stating that all products containing high level of opioid drugs should be subjected 
to aggressive surveillance and risk management (Dart, 2009).  
Criticisms of Pharmacovigilance Systems 
Throughout the years, the FDA as well as the whole system of post-marketing 
surveillance received heavy criticisms (Furberg, Levin, Gross, Shapiro, & Strom, 2006; 
Lenzer, 2004; Mitka, 2006; Ray & Stein, 2006; Strom, 2006). Critics heavily denounced 
FDA for being limited and ineffective because it only used restricted number of data 
sources such as clinical trials and spontaneous reports to determine the safety of the 
drugs. Moreover, the FDA was criticized as not having legitimate control for carrying out 
and completing post-marketing safety studies (van Grootheest & Richesson, 2012, p. 
371). According to Furberg et al. (2006), the FDA needed serious changes because the 
initial preapproval studies were designed in a way that prevented serious adverse events 
from detection. Moreover, massive underreporting of adverse events to the FDA post-
marketing surveillance system made FDA assessments of risks inaccurate. The FDA was 
unable to go after the sponsors and manufacturers who did not fulfill or ignore their post-
marketing safety study obligations. Lastly, the FDA was perceived as becoming more 
closely linked to the regulated pharmaceutical industry and weak when it came to their 
oversight abilities.  
Moreover, most post-marketing study commitments that had been planned were 
never carried out. From 1970 to 1984, around 38% of post-marketing safety studies were 
not completed (van Grootheest & Richesson, 2012). However, even though this was the 





companies who did not follow through with their commitments (van Grootheest & 
Richesson, 2012). The FDA was said to have become too close to the industry it was 
supposed to be regulating. The critics claimed that regulatory duties of the institution 
should be separated from its post-marketing surveillance activities (van Grootheest & 
Richesson, 2012). The FDA reacted to this criticism by asking the IOM to evaluate the 
US drug safety system. As such, in September of 2006, the IOM produced a report that 
claimed the FDA should monitor the safety of a drug during its whole life cycle or should 
follow the life cycle approach. By following this approach, the FDA should determine 
safety signals, design studies that would confirm these signals, assess both the benefits 
and risks of drugs, and utilize risk-benefit assessments to integrate study results and 
disclose the main findings to patients and physicians (Psaty & Burke, 2006) 
FDA’s Adverse Event Reporting System 
According to Hoffman, Overstreet and Doraiswamy (2013), more than 770,000 
injuries or deaths annually could be attributed to adverse events linked to drugs already 
approved by the FDA. It had been estimated that around 28% of these adverse events 
could have been prevented if there was an effective computerized monitoring system in 
place. The FDA currently had a database of these drug-related adverse events, which was 
the FAERS as well as an adverse event database for medical devices, was called 
Manufacturer and User Facility Device Experience (MAUDE).  
The FAERS was a database that consisted of information on the reports received 
by FDA containing information of adverse events and medication errors. The database 





biological products. The FAERS abided with the international safety reporting guidance 
provided by the International Conference on Harmonization (Sakaeda, Tamon, 
Kadoyama, & Okudo, 2013). 
This system acted as the post-market monitoring system for the FDA, which used 
historical data or information to supervise new adverse events and medication errors from 
drug and therapeutic biologic products (FDA, 2012d). This was designed to control the 
medical treatment and drug related issues that might lead to hazardous effects to the 
patients and consumer. The idea of recording and creating a computerized information 
database started due to the number of adverse events in the United States that was 
claimed to be 1 million every year, of which 44,000 to 98,000 was claimed had ended as 
fatalities (Leape, 2002).  
At present, FAERS was considered the largest database of spontaneously reported 
adverse events and medication errors worldwide (Moore, Cohen & Furberg, 2007). At 
present, this database already contained 4 million reports of these adverse events. The 
FDA distributed the data under this system to the public and the public access enabled the 
researchers or experts to conduct pharmacoepidemiological or pharmacovigilance studies 
(Sakaeda et al., 2013).  
The FAERS database had been utilized for analyzing the safety profiles of many 
different drugs. In addition, the highly suspicious drugs linked to serious adverse events 
were found by using the FAERS database, examples of which were the torsades de 
pointes (Poluzzi, Raschi, Motola, Moretti, & De Ponti, 2010). “Torsade de pointes is a 





interval on surface electrocardiogram” (Gowda, et al., 2004, p.1). Through a larger 
number of reliable reports, the FAERS database, as well as other databases for reporting 
could lead to optimized pharmacotherapy (Sakaeda et al., 2013).  
The FAERS had its advantages and limitations. The system did not necessarily 
have known disadvantages yet, but rather limitation in terms of the design. Despite the 
benefits of the system, it had its limitations, similar to other systems. The main limitation 
of the current FAERS was that the reports submitted to the FDA and integrated into the 
system lacked the comprehensive details of the consumers who experienced the adverse 
events or medication errors due to underreporting, differential reporting as well as uneven 
quality (Berlin, Glasser, & Ellenberg, 2008; Hochberg, Pearson, O’Hara, & Reisinger, 
2009).  
In general, adverse events were still underreported even with the emergence of 
spontaneous reporting systems (Figueiras, Herdeiro, Polonia, & Gestal-Otero, 2006; 
Hazell & Shakir, 2006; Lopez-Gonzales, Herdeiro, & Figueiras, 2009). While the rate of 
reporting might depend on the specific adverse event, the average rate of reporting was 
just 6% based on 37 studies (Hazell & Shakir, 2006). Various factors could explain why 
many adverse events were still not being reported, but the most critical one concerns the 
knowledge and attitude of health professionals (Lopez-Gonzales et al., 2009). Moreover, 
an educational intervention had shown to be the key to improve the rate of reporting 
(Figueiras et al., 2006). Through a patient-targeted survey, it was determined that 87% of 
patients relied on their physicians to establish if there was a possible connection between 





higher tendency to say no to the possibility rather than affirm the link (Golomb & 
McGraw, 2007). In addition, increased publicity and patient education for the FAERS 
were also important to encourage patient reporting (Du, Goldsmith, Aikin, Encinosa & 
Nardinelli, 2012). Currently, while the report rate had improved with the implementation 
of the FAERS (Rodriguez, Staffa & Graham, 2011), it was still not ideal to use the 
FAERS database in estimating incidence report rates because of the lack of a 
denominator, which signified the population size to determine utilization together with 
the number of times it occurred.  
According to the FDA (2012a), adverse events and medication errors that had 
been made by healthcare professionals or experienced by consumers were not strictly 
mandated to be reported, reporting was voluntary in the United States. The adverse event 
and medication error reports were sent to the FDA by the consumers or end-users (for 
example, physicians, pharmacists, nurses, and other healthcare professionals) (FDA, 
2012a). More so, these said individuals who had first or second-hand experience of the 
adverse events or medication errors might directly contact the products’ manufacturers to 
report the problem. The FDA expected to receive the complaint report from the 
manufacturer filed by the consumers or healthcare professionals, as this process was to be 
done as it was stipulated in the regulations. All reports were then integrated in the 
FAERS, after which it was directly sent to the FDA or reported to the manufacturers 
(FDA, 2012a). 
According to Hoffman et al. (2013), FAERS had the ability to acquire 700,000 





powerful database. The database was widely used by many regulatory agencies and the 
pharmaceutical industry to look for data regarding drug safety. However, Hoffman et al. 
(2013) raised the problems with FAERS, such as the issue of complexity and costliness 
of proprietary data mining and signaling tools utilized by the regulatory agencies and 
major pharmaceutical companies. In addition, only those familiar with relational 
databases could obtain publicly available FAERS information, which limits the use of 
this database. This was why; the FAERS database was still currently mostly inaccessible 
to majority of physicians, pharmacists and consumers.  
In addition, FAERS also suffered from limitations such as duplicate reporting, 
masking, amplifications, and insufficient information (Hoffman et al., 2013). The data on 
the FAERS might not be reliable because physicians might disproportionately report 
effects linked to newer drugs, even though other influence of other prescribed drugs and 
other factors might be the real cause of the adverse events. Data might also be 
questionable because physicians might have been influenced by publicity and marketing 
conditions. The lack of true incidence rates as well as accurate usage data could make the 
data in the FAERS unreliable (Hoffman et al., 2013). 
Sentinel Initiative  
To develop and implement the Sentinel System, the FDA performed pilot 
programs to aid in the forming of scientific methodologies, identifying data infrastructure 
needs, and enlightening the agency on how to establish strong data governance to form an 
accurate governance structure to ensure data privacy and security (Robb et al., 2012). 





that a distributed data system model involving voluntary participants was the key 
approach that could be used for coming up with an active safety surveillance system. 
Through this surveillance model, the FDA could make sure that data would stay in its 
local environment, unlike to a centralized approach, which would entail the consolidation 
of all data into one physical location (Robb et al., 2012).  
The Mini-Sentinel pilot project was comprised of 20 organizations, led by the 
Harvard Pilgrim Health Care Institute (HPHCI) (Robb et al., 2012). The Mini-Sentinel 
program was a pilot under the FDA Sentinel initiative, as an effort to implement a 
national system that would assess the safety of medical products. The Mini-Sentinel was 
focused on signal refinement, or the improvement in the process of the assessing the 
magnitude of suspected links between specific medical products and specific adverse 
health outcomes (Robb et al., 2012). The FDA selected the particular product-outcome 
pairs, as it was the body most knowledgeable of the product. Under this program, the 
FDA differentiates between signal generation, signal refinement as well as signal 
evaluation (Robb et al., 2012). Signal generation involved the carrying out of statistical 
methods to discover possible safety signals among the pairs of non-pre-specified medical 
products and specific adverse outcomes. On the other hand, the process of signal 
refinement involved the identification of possible safety signal to establish more clearly 
whether evidence existed to provide a basis for the particular product-outcome pairs. 
Lastly, signal evaluation involved the attempts to assess the causal links between specific 
medical products and adverse outcomes by conducing epidemiological analysis (Robb et 





operations as part of its standard practice. However, these activities were still included in 
the Mini-Sentinel Post-Licensure Rapid Immunization Safety Monitoring or PRISM 
program that was already exploring this capability in federal vaccine monitoring 
activities (Nguyen, Ball, Midthun & Lieu, 2012). The ongoing Mini-Sentinel hoped to be 
able to do the whole spectrum of surveillance activities, or in other words, it was able to 
carry out signal generation, to signal refinement and then to signal evaluation activities. 
The collaborators behind the pilot project had worked since 2011 to assess some 
of the important issues for forming active medical product surveillance system in the 
United States (Robb et al., 2012). This included the best statistical and epidemiological 
approaches to use and what data and infrastructure were necessary for accurate 
surveillance investigations. The collaborators also assessed what kind of governance 
structure would have to be in place to support the initiative. Mini-Sentinel had been 
successful in serving as a general-purpose vaccine safety monitoring system (Robb et al., 
2012). 
Platt et al. (2012) assessed the Mini-Sentinel program, which designed different 
methods, tools, resources, policies, and procedures that could be used for the collection, 
analysis, and surveillance of electronic healthcare data. The data collected encompassed 
drugs, biologics, as well as medical tools (Platt et al., 2012).  
Within two years of its existence, the Mini-Sentinel program had 31 academic and 
private organizations associated with it (Platt et al., 2012). Platt et al. (2012) found that 
the Mini-Sentinel program employed various activities such as the robust surveillance of 





to secure additional types of data. The data were sourced from different electronic health 
records and registries. The Mini-Sentinel program also had the ability to form or design 
new methodological capabilities and provided an approach to identifying and verifying 
additional and relevant health outcomes (Platt et al., 2012). 
According to Forrow et al. (2012), the Mini-Sentinel Program was remarkable 
because it had its own organizational structure as well as principles that regulated its 
operations. These policies and structures allowed it to influence the structure and purpose 
of the Sentinel System (Forrow et al., 2012). The Mini-Sentinel program was also 
committed to the goal of the Sentinel Initiative, which was to ensure drug safety by 
regulating the ADRs of drugs already marketed to the public (Forrow et al., 2012). The 
program abided by the principles and regulations that uphold fair information practices 
(Forrow et al., 2012). As such, the privacy of individuals and the confidentiality of 
healthcare data were observed. Still, the success of this initiative still remained largely 
upon the users’ satisfaction (Forrow et al., 2012). 
Effects of Pharmacovigilance 
According to Behrman et al. (2011), the FDA Sentinel Initiative served as an 
additional tool for the FDA to evaluate the safety of medical products, and more 
importantly, acted as a national resource for the FDA to take advantage of investigating 
medical product performance. Moreover, the Sentinel Initiative became an early working 
model for secondary uses of data, and a national resource of a learning healthcare system. 
Robb et al. (2012) explained that the FDA Sentinel Initiative was borne from responses to 





initiative was intended to provide advantage to existing healthcare information to allow 
the FDA to perform active post-market safety surveillance in support of the current 
surveillance systems it had (Robb et al., 2012). 
According to Robb et al. (2012), the idea of secondary use, or utilizing data 
collected for other intentions, such as electronic health record data initially recorded for 
patient care or insurance claims data utilized for reimbursement was not a new one. 
Nonetheless, due to the expansion of the availability of these types of data, based on the 
passing of the US Health Information Technology for Economic and Clinical Health 
(HITECH) Act, more attention had been given to the leveraging of these data for 
purposes they were not intended for, such as updating the public on specific health issues. 
One of these issues was the safety surveillance of medical products (Robb et al., 2012). 
The FDA, through the use of various administrative and claims databases, as well as 
electronic health record systems and registries, would now have the ability to scrutinize 
regulated medical products nearly as fast as real time and to better comprehend product 
safety (Robb et al., 2012). 
According to Robb et al. (2012), the system being designed and developed under 
the auspices of the Sentinel Initiative would be able to aid the FDA in discovering and 
analyzing post-market safety signals through signal generation, signal refinement, and 
signal evaluation, which referred to the concern over an excess of irregular and negative 
events when compared to what was traditionally associated with a product's use. Signal 
refinement specifically allowed the FDA to assess a drug at various times during its life 





FDA might conduct additional assessments to validate the signals it received. The 
validation process was performed to ensure that the adverse outcome from the drug was 
not spurious (Robb et al., 2012). Overall, the Sentinel Initiative was helpful to the FDA 
when making regulatory decisions. 
Summary 
The current FDA consumer safety surveillance system used the FAERS, which 
had limitations, including not allowing real time data collection. In response to these 
limitations, the FDA launched the Sentinel Initiative in 2008 (Platt et al., 2012). This 
study provided a comparative case study between the two systems, investigating the 
influence of the Sentinel Initiative on users of FAERS. 
The review of literature outlined the existing knowledge pertinent to this study. It 
illuminated the need for ADR reporting systems and their benefits. It also specifically 
covered the Sentinel Initiative and the Mini-Sentinel Program, which were the programs 
of interest for the proposed study.  
The next section covered the methodology used in carrying out the proposed 
study, which was approved by Walden IRB committee. The study implemented a 
comparative case study design, which was qualitative in nature. Survey questionnaires 
used to determine the perceptions of the participants regarding the costs and benefits of 
the Sentinel Initiative compared with the current FAERS surveillance methodology. The 
data analysis technique that used was content analysis, which involved the development 





Chapter 3: Research Methodology 
The purpose of the comparative case study of the current FAERS surveillance 
system and the new FDA Sentinel Initiative was to determine the potential impact and 
benefits of the Sentinel Initiative in terms of consumer safety. Currently, the reporting 
system used by the FAERS was voluntary and quarterly, and data was entered from the 
point of care (Powers & Cook, 2012). Instead of depending on point-of-care data 
collection, the Sentinel Initiative had access to multiple existing data systems such as 
electronic health record systems and medical claims databases in real time (Platt et al., 
2009). 
This was a qualitative study was focused on the perceptions of individuals who 
had worked closely with the FAERS program and were familiar with the Sentinel 
Initiative. As such, no quantification of data waswas carried out to compare information 
on the two programs. Instead, the responses of participants regarding their perceptions 
was used to illustrate differences between the two programs. In this study, the two cases 
referred to the perceptions of the FAERS and perceptions of the Sentinel Initiative. This 
chapter presents details of the design, sampling and sampling methodology, data 
collection methodology, and data analysis. 
Research Design and Rationale 
In general, qualitative studies were different from quantitative studies in the sense 
that qualitative studies permit the study of a particular phenomenon in depth within the 
participants’ natural settings (Denzin & Lincoln, 2005). Qualitative research is 





performed through interviews, which allowed interviewees to expound on their answers 
without being limited by the predetermined choices for answers or the need to write down 
answers to questions (Moriarty et al., 2011). Qualitative designs were beneficial when 
existing research in an area was limited. Moreover, given the limitations of time, 
qualitative data was considered appropriate for this study. 
Case studies were qualitative methods that allowed for in-depth and multifaceted 
explorations to generate rich knowledge about a given subject (Crowe et al., 2011). 
According to Zainal (2007), case study enabled the researcher to explore and understand 
complicated issues. Case study research could be considered a robust approach for 
understanding issues holistically and deeply (Zainal, 2007). Researchers who used a case 
study method could closely analyze the data gathered within a specific context (Zainal, 
2007). The method was also appropriate for studies with a small geographical area or a 
very limited number of participants. It was also the best method for investigating real-life 
issues because it allowed for a detailed contextual analysis of a small number of events as 
well as conditions and their relationships to each other (Zainal, 2007). 
According to Zainal (2007), case studies had various advantages. Case study 
research allowed for examination of data within the situation in which the activity 
happened. Moreover, the case study method allowed the researcher to explore or 
characterize the data within real-life contexts as well as explained the complexities 
associated with the real-life issues that survey research or experimental methods could 
not capture (Zainal, 2007). When multiple cases were examined and compared, then it 





study, the first case was the perceptions of the old system and the second case was the 
perceptions of the new system.  
Methodology 
Population 
The target population included safety professionals from drug companies who had 
self-reported knowledge or expertise in assessing consumer impact. The participants were 
selected from various departments within pharmaceutical companies and across 
geographical locations. The participants were subject matter experts in the field of 
pharmacovigilance.  
Sample and Sampling Procedures 
Samplingincluded participants at different levels from different therapeutic 
departments such as pain and inflammation, cardiovascular, and psychiatric and mental 
health. The geographical locations included selected pharmaceutical companies in the 
United States. The participants were(a) had worked closely with the current FAERS 
surveillance system and were familiar with the FDA’s Sentinel Initiative and (b)were 
from prominent pharmaceutical companies involved in the programs of focus in this 
study. Criteria confirmation waswas performed by asking participants questions that 
conformed to the criteria for inclusion during the time the interview was to be scheduled.  
Mason (2010)  stated that the required sample size for qualitative studies could be 
determined based on the point of data saturation. Saturation indicated that the data 
gathered had reached consensus, and using more resources by recruiting more 





posited that qualitative case studies usually had small sample sizes as opposed to 
quantitative methodology, which normally relied on larger sample sizes. Polkinghorne 
(2005) stated that qualitative data were collected in the form of written or 
verbal language, and the sample size was not the primary focus. In addition, 
Patton (2005) stated that there were no specific standards for sample size in qualitative 
studies, and that, “sample size depends on what you want to know, the purpose of the 
inquiry, what’s at stake, what will be useful, what will have credibility, and what can be 
done with available time and resources” (p. 244). However, a sample size of 10-20 
participants was usually considered sufficient to achieve data saturation because a review 
had shown that the small sample size could facilitate gathering enough detailed accounts 
of personal experiences to arrive at a consensus among answers (Mason, 2010). Hence, 
20 participants who had worked closely with the FAERS program and were familiar with 
the Sentinel Initiative were recruited for this study. 
For sampling methodology, purposive sampling was used with the snowball 
technique for more efficient recruitment of participants. According to Latham (2007), 
purposive sampling referred to choosing a sample based on the researcher’s knowledge of 
the population and its elements and matching these elements to the nature of the research 
aims. As such, the population was not randomly selected. Instead, they were chosen 
because they could answer the questions regarding a specific matter or product. This 
method was best for research studies that included subjects who are part of a larger 
population that were easily identified but enumerating them all was impossible (Latham, 





technique used. Snowball sampling took advantage of social ties and network referrals of 
potential participants who possessed the characteristics for inclusion in the study 
(Latham, 2007). According to Latham (2007), this would include the researcher 
depending on previously identified subjects to identify others who had similar 
characteristics. To recruit samples using purposeful sampling with snowball sampling, 
the participants were sought within pharmaceutical companies in the United States who 
were selected because of their involvement with the FAERS program. Participants were 
only those who met the inclusion criteria of having worked with the FAERS and were 
familiar with the new Sentinel Initiative. The nature of the study was discussed with the 
participants. The contacted participants referred the study to other individuals who fit the 
inclusion criteria. The prospective participants were contacted through formal invitation 
letters.  
An informed consent form (Appendix B) was attached with the formal invitation 
letter (Appendix A) sent to potential participants. The informed consent form included a 
brief description of the study, the purpose, and the role of the participants. Participants 
were also informed that their interviews would be recorded. Once the potential 
participants agreed, they signed the informed consent to signify their acceptance of 
involvement in the study. After signing the informed consent, the participants brought the 
forms to the interview; unsigned forms were also available during the interview for 
participants who had forgotten to bring their signed forms. The participants were 
contacted via telephone or email to arrange a convenient date and time for the telephone 





and reduced the travel burden for the participants. Specifically, each participants’ was 
asked for his or her consent prior to the beginning of the telephone interview. The 
telephone interview lasted approximately 45 minutes. Participants who preferred the 
telephone interview faxed or emailed the copies of their informed consent with their 
signatures.  
Data Collection 
Data collection was facilitated with the use of semi-structured interviews. Prior to 
the interview, the participants were reminded of the content of the informed consent. 
They were also reminded that participation was voluntary, that their identity would be 
kept confidential, that the interview would be recorded, and that all files and notes would 
be kept secured inside a locked cabinet in a private office and would be destroyed after 5 
years from the completion of the study.  
To facilitate the semi-structured interviews, an interview guide was used that 
contained questions that were focused on gathering answers that were in line with the 
purpose of the study. To make sure that the participants could easily and accurately 
understand the questions in the interview guide (Appendix C), a pilot study was 
conducted for comprehensibility. In the pilot study, five participants were recruited with 
the same qualifications to participate in the interview (from the pharmaceutical 
companies selected for this study). These pilot study participants interpreted each 
question and discussed their feedback during a one-on-one session after the completion of 
the interview. Notes were taken of the feedback and no change in the interview guide was 





were thanked. The participants were given an opportunity to ask questions and request 
clarifications, which were addressed. 
Though the interviews were expected to last 45 minutes, there was no time limit 
as each interview was dependent upon the flow of the conversation between me and the 
respondent. The entire data collection process, which included the recruitment process, 
pilot study, and completion of the 20 interviews, lasted twelve weeks during Fall 2015. 
Data Analysis Plan 
To analyze the transcribed data, thematic content analysis was used. Content 
analysis led to the identification of important themes. Content analysis was “a research 
method for the subjective interpretation of the content of text data through the systematic 
classification process of coding and identifying themes or patterns” (Hsieh & Shannon, 
2005, p. 1278). The thematic pieces were weaved together to form an integrated picture 
that was aligned with the research questions, which were as follows: 
Research Question 1: What are the prospective benefits of the FDA’s Sentinel 
Initiative as compared with the FAERS surveillance methodology? 
Research Question 2: What are the challenges and negative impacts of the FDA’s 
Sentinel Initiative as compared with the FAERS surveillance methodology? 
Research Question 3: What are the lessons learned that can enhance the scope of 
the Sentinel Initiative?  
According to Polit and Beck (2004), the researcher began the analysis of data by 
looking for themes, which involved looking for commonalities, natural variations, and 





steps of Braun & Clarkes’ (2006) thematic analysis were used as a guide, which consisted 
of the following: 
1. Familiarization with the data: This involved transcribing, reading, and re-
reading the audio-recorded interview data, and taking note of initial ideas. 
Final raw data was the transcripts for each of the interview sessions.  
2. Codes generation: Code of interesting features of the data were developed in a 
systematic fashion as applied to the entire data set. The entire data set was 
coded based on the coding scheme developed. 
3. Searching for themes: the codes were collated into potential themes by 
gathering all data relevant to each potential theme. 
4. Theme review: The themes were checked in relation to the coded extracts and 
the entire data set. Through this step, a thematic map of the analysis was 
generated.  
5. Theme definition: Themes represented the most cited codes within a category. 
Codes, categories, and themes were analyzed. These were defined accordingly 
based on the codes they contained. Codes represented the smallest unit of idea 
or information relevant to the study. Categories were composed of interrelated 
codes that pertained to a larger but similar idea.  
6. Report generation: The final report of the data analysis was developed and 
selected vivid and compelling examples to further explain the findings. For 
each category, tables contained the codes that emerged from that category. 





All of the responses were read and analyzed; then extracted the significant 
statements that pertained directly to the issue. Following this, meanings for significant 
statements were formulated and categorized these into clusters, which were considered to 
be the themes. Following these steps, the findings were integrated into an exhaustive 
description. Then a comprehensive description of the phenomenon under study was 
formed.  
Validity 
The participants were recruited for the study. The semi-structured interviews with 
the 20 participants were conducted. It was ensured that the sessions were productive in 
eliciting useful information from the participants by following the proper techniques for 
one-on-one interviews. The interview guide was followed to ensure validity and 
reliability. It was ensured the study was not impacted by any bias to ensure that data was 
accurate and objective. To minimize bias, the study’s credibility, dependability, and 
transferability was upheld. Below were the ways to ensure these respectively. 
Credibility and Dependability  
To ensure credibility, member checking were performed through verification of 
accuracy of conclusions with participants (Thomas & Magilvy, 2011). The researcher 
was as transparent as possible with the participants, by sharing the interpretations and 
conclusions with them. Member checking was performed to double check if the 
information transcribed and written corresponds to what the participants said (Thomas & 
Magilvy, 2011). Member checking was done by asking participants to review the 





the researcher audiotaped interviews, with the consent of the participants, and later on, 
the researcher transcribed the interviews verbatim. An audit trail had been kept and used 
by the researcher where observations were recorded and made available for peer 
reviewers (Thomas & Magilvy, 2011). Pseudonyms, known to the researcher alone, were 
used to replace all these identifying information and transcript of a participant. For report 
generation, aggregate data was used; for instances that required the researcher to single 
out a particular data point, pseudonyms was used instead. 
Transferability  
Thomas and Magilvy (2011) claimed the association between transferability and 
external validity. Transferability involved the study’s ability to transfer findings to 
another population different from the one used by the researcher of the original study 
(Thomas & Magilvy, 2011). All the data collected, audiotapes, and journal notes, and 
transcriptions were kept in their original form. This was done to allow easier access 
should there be a need to recreate the study in a different setting. The data did not contain 
any names. Pseudonyms, known to the researcher alone, were used to replace all these 
identifying information to ensure the confidentiality of the participants. 
Ethical Procedures 
Researchers needed to ensure that they recognized and protected the rights and 
general well-being of their participants (Resnik, 2010). Ethical lapses in research could 
harm human and animal subjects, students, and ultimately, the public (Resnik, 2010). 
Before participants actually took part in the study, they were asked to sign an informed 





they partake in the study. The ethical issues covered by the informed consent were 
confidentiality and voluntary nature of participation. Upon agreeing, the participant was 
to sign the consent form as proof that they agreed to participate in the study. 
Confidentiality was an important issue that must be addressed in using human 
participants in a research. To do this, any information was deleted that might identify the 
respondents in any way. Pseudonyms, known to the researcher alone, were used to 
replace all these identifying information. For report generation, aggregate data was used; 
for instances that required to single out a particular data point, pseudonyms was used 
instead. The participants were also informed that the interview would be recorded. After 
transcribing, each respondent could review the transcripts of their interviews for mistakes 
and make requests for removal of any undesirable word or phrase. This process was 
called member checking. According to Harper and Cole (2012), member checks were 
important to make sure that an authentic representation was made of what was expressed 
during the interview sessions.  
Being a participant in the study was voluntary; and hence, they would or would 
not agree to sign the consent form. Voluntary participation also implied that there was no 
reward or consequence for being a participant of the study. Even if they had already 
consented to participate, participants still had the option of termination their participation 
of the study, without having any consequence on their part. They also had an option to 
choose not to answer any particular question, which they felt uncomfortable answering. 
All files containing data related to the study, including all physical and electronic 





kept inside a locked cabinet located at a private office where I had access to these files. 
These files would be kept for five years after the entire study had been finished and 
completion of this dissertation. After five years, they would be destroyed through 
shredding or burning. 
Summary 
The purpose of this comparative case study of the current FAERS surveillance 
system and the new FDA's Sentinel Initiative was to determine the impacts and benefits 
of the Sentinel Initiative in terms of consumer safety. Currently, the reporting system 
utilized by the FAERS was voluntary and quarterly (Powers & Cook, 2012). Instead of 
depending on point of care data collection, the Sentinel Initiative would access multiple 
existing data systems such as electronic health record systems and medical claims 
databases (Platt , Wilson, Chan, Benner, Marchibroda, & McClellan, 2009). 
This was a qualitative study focusing on the perceptions of individuals who 
worked closely with the FAERS program and were faimiliar with the new Sentinel 
Initiative. As such, no quantification of data was carried out to compare information on 
the two programs. Instead, the responses of participants regarding their perceptions were 
illustrated any differences between the two programs. This chapter showed that the 
research questions are in line with the purpose of the study, a comparative case study 
approach was chosen for this study. Semi-structured interviews were used to gather data 
for the study from 20 participants who worked with the FAERS program and familiar 





snowball sampling. To analyze data, content analysis was used. The next chapter will 





Chapter 4: Results 
The purpose of this comparative case study of the current FAERS surveillance 
system and the new FDA’s Sentinel Initiative was to determine the potential impact and 
benefits of the Sentinel Initiative in terms of consumer safety. Currently, the reporting 
system utilized by the FAERS is voluntary and quarterly, and data was entered from the 
point of care (Powers & Cook, 2012). Instead of depending on point-of-care data 
collection, the Sentinel Initiative had access to multiple existing data systems such as 
electronic health record systems and medical claims databases in real time (Platt et al., 
2009). There were differences between the FAERS and the Sentinel Initiative that were 
identifiable by the pharmacovigilance experts. 
The following were the research questions of this study: 
RQ1. What are the prospective benefits of the FDA’s Sentinel Initiative as 
compared with the FAERS surveillance methodology? 
RQ2. What are the challenges and negative impacts of the FDA’s Sentinel 
Initiative as compared with the FAERS surveillance methodology? 
RQ3. What are the lessons learned that can enhance the scope of the Sentinel 
Initiative?  
FAERS was known to be a useful tool for the FDA to ensure compliance with 
reporting regulations and responding to outside requests for information. The reports in 
FAERS were evaluated by the FDA and clinical reviewers in the Center for Drug 
Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research 





and safety of the consuming public (FDA, 2016). The Sentinel System enabled FDA to 
actively query diverse automated health care data holders - like electronic health record 
systems, administrative and insurance claims databases, and registries - to evaluate 
possible medical product safety issues quickly and securely. The FDA Adverse Event 
Reporting System (FAERS) was a database that recorded the relevant information on 
adverse events of drugs or medication errors that were submitted to FDA (FDA, 2016). 
The database of the FDA was designed to support the FDA’s program for the 
safety surveillance of pharmaceutical medications for drug and therapeutic biologic 
products. FAERS captured data by either consumer reporting directly to drug 
manufacturers or by calling the FDA directly and which is why there was a limited set of 
information going to system. On the other hand, the FDA’s Sentinel Initiative was a 
national electronic system that would allow the FDA to track the safety of medications, 
medical devices, and drugs upon reaching the market. The FDA was able to query 
consumers and examine the health record systems to ensure that drugs were safe for 
human consumption (FDA, 2016). The Sentinel System allowed the FDA to monitor the 
safety of drugs and medical products including devices with the assistance of many 
collaborating institutions throughout the United States. Data partners in this initiative 
included medical centers, health maintenance organizations (HMOs), and health care 
systems like hospitals (FDA, 2016). 
Pilot Study 
To facilitate the semi-structured interviews, an interview guide was used that 





the study. To make sure that the participants could easily and accurately understood the 
questions in the interview guide; a pilot study was conducted for comprehensibility. Five 
participants were recruited with the same qualifications to participate in the interview 
(from the pharmaceutical companies selected for this study).  These pilot study 
participants interpreted each question and discussed their feedback during a one-on-one 
session after the completion of the interview. At the end of the interview, the participants 
were thanked.  
Five participants were recruited for the pilot study. The participants worked in 
pharmaceutical companies and had experience in the pharmacovigilance department. The 
participants were interviewed separately and their feedback was sought about the content 
of interview questions. No change in interview guide was required. Data collection was 
continued with other participants. 
Setting 
The participants included safety professionals from drug companies who had self-
reported knowledge or expertise in assessing consumer impact. The participants were 
selected from various departments within pharmaceutical companies and across 
geographic locations. The participants were subject matter experts in the field of 
pharmacovigilance. The setting of the study emphasized the importance of reporting the 
adverse impacts of medication and drugs.  
Summary of Demographic Information 
 The study included 20 interviewees who had different numbers of years of 





pharmaceutical companies and had previous experience in pharmacovigilance 
departments or were working in the departments at the time of the study. The participants 
were taken from different levels in their respective pharmaceutical companies, including 
junior level and senior levels positions. Some had full-time positions or some were 
consultants in pharmaceutical companies at the time of the study or in the past. 
Participants who were at junior levels had at least 2 years of experience, and others had 
five years of experience or more in the field of pharmacovigilance. Participant 
demographics are presented in Table 2. 
Table 2  
Demographics of the Interviewees 


























Data collection was facilitated with the use of semi-structured interviews. Before 
each interview began, the participants were reminded of the content of the informed 
consent. They were also reminded that their participation was voluntary, that their 
identity would be kept confidential, that the interview would be recorded, and that all 
files and notes would be kept secured inside a locked cabinet in a private office. These 
files would be destroyed after 5 years from the completion of the study.  
The semi-structured interviews were expected to last 45 minutes. However, the 
interviews had no time limit because each interview was highly dependent on the flow of 
the conversation between me and the respondent. The entire data collection process, 
included the recruitment process, pilot study, and completion of 20 interviews, lasted 
twelve weeks. Data saturation was met after interviewing 20 participants in answering the 
research questions of the study.  
Data Analysis 
The data analysis used was cross-case analysis, a method of research that allowed 
the mobilization of knowledge from several case studies (Khan & VanWynsberghe, 
2008). The cross-case analysis allowed for comparison of similarities and differences in 
the outcome based on the interviews conducted (Maben & Penfold, 2015).  
Provisional deductive codes were identified from the predetermined input, output, 
and expected outcome of the two programs. These deductive codes helped in identifying 
relevant inductive information concerning the program. The five deductive codes 





voluntary reporting, and (e) systematic database. From these codes, 29 codes were 
identified covering five interview questions responded by 20 participants. Eighty pages of 
transcripts were read and the codes were sorted, which are presented in Appendix D.  
The 29 codes that emerged from the collected data were data collection, use of 
health data, active system, voluntary reporting, systematic database, privacy, relative 
assessment, unexpected adverse effects, threats to public health, health safety, patient-
centeredness, coincidental occurrences, risk evaluation, reporting model, post-drug 
approval activities, evaluation of products, responsibility, accountability, preventive 
action, alerting the public, evidence-based, vigilance, accessibility, inclusive, discovery 
of new risks, other stakeholders, drug safety, opportunity to improve healthcare 
professionals, and disease occurrence. For each emerging code, a meaning was 
determined based on the verbatim provided by one or more participants.  
For the data collection code, it was determined that FAERS and Sentinel collect 
data from patients regarding the adverse effects of drugs. The sample quote from 
participant 17 was: 
The availability of vast volume of data which includes not only the drug reaction 
details but also the information such as medical history of the patient, personal 
details such as age etc. also all this information will help us derive relevant and 
durable information from the data.   
 
For the use of health data code, it was determined that health data is used for the 
record of FDA. The sample quote from Participant 14 was, “There are various 
organizations and to be exact I believe 18 organizations that are involved in retrieving 
health data.”  The Sentinel Initiative is an active system of reporting was determined for 





active system they have immediate results.”  Participant 1 responded, “FAERS is 
basically everything is voluntarily done most of the time it is more specific to particular 
patients.” For the voluntary reporting code, it was determined that the voluntariness of 
reporting is evident in the regulation. For systematic database, Participant 7 stated, 
“FAERS is the FDA adverse events reporting system. It’s a database that contains the 
information on Adverse events (AE’s) and medication errors” and it was determined that 
the reporting the ADRs allow having a systematic database. Participant 6 stated, “I really 
see here is the privacy issue- The HIPAA compliance. I don’t know if the patients would 
like to share their information to a third party”, which resulted in a privacy code. It was 
determined that privacy of the individuals who report adverse effects might be at stake. 
Similarly for relative assessment code, it was determined that there can be differences in 
how a person assesses or evaluates the effects of drugs.  For the relative assessment code, 
it was determined that there can be differences in how a person assesses or evaluates the 
effects of drugs. Participant 8 responded: 
With the FAERS system addressing adverse differential FAERS is dependent on 
whether the patient really calls FDA or health care company and that one is 
limited. Whereas with Sentinel the patient may be either talking to healthcare 
profession that I had reaction with drug and it might get reported much more 
better than the FAERS system where the patient might even not know where to 
report. 
 
For the unexpected adverse effects code, it was determined that the unexpected adverse 
effects of drugs should be reported in order to be prevented. Participant 12 responded, 
“There would be more clinical information available regarding the adverse effect and 
what was happening so that would be one major benefit”. Participant 2 mentioned, “I say 





system.” It was determined that the adverse effects of drugs pose threats to public health 
which led to the threats to public health code. Health safety of patients can be achieved if 
drugs are safe was determined for the health safety code as Participant 2 stated, “The 
potential benefits of the patients ultimately the FDA was created to benefit the patients 
and consumers and the larger population will be benefited by this and more genotyping 
and genomics data.” For the patient-centeredness code, it was determined FAERS and 
Sentinel Initiative are focused on the welfare of patients. Participant 20 stated: 
I think it’s mostly patients safety, they are having a lot of information sharing it 
they are able to share it, they are compiling they are getting a great deal more info 
on all these products hopefully to be used for a patient safety. 
 
Coincidental occurrences on patients that do not have direct correlation to the drugs 
might be mistaken as adverse drug effects that were determined for the coincidental 
occurrences code. Participant 2 stated: 
I can confirm it if you like all the adverse reactions that happened whether it was 
on doctors clinic or it happened anywhere else in the hospital only 6-10% were 
reported since the institution established FAERS whereas the sentinel program 
because it is not asking you report anything it is asking you to just keep your data 
in a particular format. 
 
For the risk evaluation code, it was determined that the risks on drugs will properly be 
assessed if there is a proper reporting model.  Participant 13 stated: 
I think the challenges are that you know with a lot of data you also comes with it 
is noise and you know the quality of data and probably you can have where 
signals will get lost and then you have different interpretations of signals of what 
is actually a risk and what is I think it gets a little bit murky with that large 
amount of data. 
 
The reporting model of how adverse drug effects are recorded should be systematic is 





have a separate method they can use to overcome under reporting of worst events so if 
the data is not there they can obtain any additional information.” Post-drug approval 
activities must be evaluated to ensure the safety of the public was determined for the 
post-drug approval activities code. Participant 4 stated: 
So basically they use all these query methods so that they can query these large 
database to determine to get the desired results of what are on what features are 
they looking for and what kind of problems they want to solve or especially what 
drug they want to improve. 
 
The proper evaluation of products should be the priority in order to ensure health safety 
was determined for the evaluation of products code. Participant 18 stated, “Evaluation is 
done principally by FDA and they will be the one who will analyze the data and gather 
critical information out of this.” For the responsibility code, it was determined that there 
should be a government agency that regulates drugs in order to monitor responsibility on 
the safety of drugs. Participant 20 stated, “So here again I think the agency has the 
ultimate responsibility when it comes to reporting though in general it is on … it’s on the 
health care professionals and consumers.”  
For the accountability code, it was determined that there should be a government 
agency that regulates drugs in order to monitor accountability on the safety of drugs. 
Participant 17 stated, “Again the FDA, the stakeholders are solely responsible for 
implementing and evaluating these methods.” Participant 13 stated, “I think there are may 
be 18 organizations collecting this data help data warehousing and ensure companies like 
that have access to vast of data and vast of health data.” The reporting model is a form of 
preventive action to ensure that future similar incidents will be prevented which was 





that the public has the right to know on the possible adverse drug effects based on the 
experience. Participant 17 stated: 
The potential challenges which I am looking upon in this under reporting  of 
adverse from these methods is to instill a sense of security amongst the patients 
and we have to educate them that their personal  data is only used for medicinal 
and research purposes. The meaning for evidence-based code was determined as 
the reporting of adverse drug effects by the patients will allow evidence-based 
conclusions.  
 
Participant 19 stated, “Doctor must have prescribed something and there must be some 
evidence and records they don’t have to wait for many years.” Vigilance in the 
pharmaceutical industry must be improved was determined for the vigilance code. 
Participant 16 stated, “I mean all the stake holders that are involved should be responsible 
whether be the manufacturers or the distributors or the FDA or the healthcare 
professionals or even the patient.” For the accessibility code, it was determined that the 
records and data collected should be made accessible to the public. Participant 16 also 
stated, “Information is generally documented within the healthcare providers database it’s 
more readily accessible to FDA to perform to better evaluate the data.” For the inclusive 
code, it was determined that a more inclusive system should be created so that the 
development will go beyond research purposes. Participant 5 responded, “To obtain 
extensive stakeholders and partners to participate in this imitative there will have to some 
kind of method to educate consumer for this work so that they may be able to share their 
health care info to the database.” It was determined that new risks on the adverse drug 
effects will be prevented for discover of the new risks code. Participant 4 stated: 
That it can eliminate under reporting to extent but it will be still be there because 





are linked and they have access to those databases then  they will have better 
analysis to problems of adverse drug reactions. 
 
Participant 5 stated, “Consumer may not allow releasing their health care info and they 
need to increase their stakeholders if they want to expand and implement all over the 
country.” It was determined that a more inclusive progress in the field of 
pharmacovigilance is possible if there are more stakeholders that led to the other 
stakeholder’s code. For the drug safety code, it was determined that drug safety should be 
prioritized in ensuring that there are proper reportorial mechanisms. Participant 17 stated, 
“It will help derive the FDA and to evaluate about a drug and take some safety measures 
about a drug.” For the opportunity to improve healthcare professionals code, it was 
determined that healthcare professionals will improve their performance if the drugs are 
properly regulated. Participant 5 stated, “So the challenge again would be the lack of 
partnership, they have to increase their partnership to all physicians, pharmacies in order 
to expand their data base.” Lastly for the disease occurrence code, it was determined that 
disease occurrence can be lessened if there is proper regulation of drugs available in the 
market. Participant 19 stated, “There are some other diseases and other things that I have 
and if I am going to take this medication it going to have an impact on me.” 
 As codes emerged in the transcripts, I reviewed and categorized these codes for 
further analysis. Out of the 29 codes, I identified six categories. These were: data 
collection, patient’s health, regulatory mechanism, preventive measure, other 
stakeholders, and drug manufacture.  For the first category, the associated codes for data 
collection were data collection, use of health data, active system, voluntary reporting, 





based on associated codes derived from participant’s response. The meaning from first 
category was determined as FAERS and Sentinel Initiative provide a systematic data 
collection for a database that would use health data to improve public health. For the 
second category, the associated codes for patient’s health were unexpected adverse 
effects, threats to public health, health safety, patient-centeredness, and coincidental 
occurrences. The meaning from second category was determined as the adverse effects of 
drugs will be recognized and the safety of the patients and the public will be prioritized.  
For the third category, the associated codes for regulatory mechanism were risk 
evaluation, reporting model, post-drug approval activities, and evaluation of product 
responsibility and Accountability. The meaning was determined as the reporting model 
provides a regulatory mechanism after the drug approval activities in order to evaluate 
the medicinal products. For the fourth category, the codes for preventive measure were 
preventive action, alerting the public, and evidence-based vigilance. The meaning derived 
from this category and associated event was the presence of FAERS and Sentinel 
Initiative improves the vigilance of the public towards the adverse effects of drugs. The 
fifth category, other stakeholder were based on codes such as accessibility, inclusive, 
discovery of new risks, and other stakeholders. The meaning determined from these 
codes and category was a more inclusive database will include other stakeholders and 
make the records more accessible. The sixth category was drug manufacture which was 
based on codes such as drug safety, opportunity to improve health care professionals, and 





availability of a surveillance system such as FAERS and Sentinel Initiative will improve 
drug safety. 
Themes were derived from analyzing the responses of the participants in the 
interviews. Each interview was thoroughly read and analyzed. The codes were created 
based upon analyzing each interview session. The cross-case analysis was conducted by 
analyzing the codes derived per interviewee. Twenty nine codes were derived and these 
codes were divided into six categories. These themes are further discussed in the latter 
part of the chapter. 
 Evidence of Trustworthiness 
The results of the study were credible and dependable. The interviews verbatim 
were transcribed so as not to avoid misinterpretation or poor recall of the answers 
provided by the participants. It was also confirmed from the audio whenever there were 
ambiguous content within the transcripts of the interview. To ensure dependability, it was 
ensured an audit trail that was available for peers to review. The names of the participants 
were maintained confidential. This improved that trustworthiness of the study, because 
revealing the identities of the participants might hamper their intent to be open and 
prudent in providing the information for the research. The transcripts used for the study 
were faithful to the original interviews conducted with the participants.  
Thomas and Magilvy (2011) claimed the association between transferability and 
external validity. Transferability involved the study’s ability to transfer findings to 
another population different from the one used by the researcher of the original study 





ADRs were reported. The demographic profile of the interviewees indicated that the 
study would have similar results when a different set of pharmacovigilance experts were 
interviewed. The external validity of the study was ensured by the strict scrutiny of the 
data collected from the interview. To ensure transferability of the study, the audio files 
were promptly recorded of the interview and the verbatim transcript. Pseudonyms, known 
to the researcher alone were used to replace all these identifying information to ensure the 
confidentiality of the participants. The snowballing techniques were utilized and I met 
different people who worked in pharmacovigilance department. The participants who 
agreed to participate in the study had self-reported knowledge of Sentinel initiative. 
These participants worked closely in drug safety department of pharmaceutical 
companies. Hence, they had work closely with FAERS. 
Results 
Based on the analysis of the codes and categories, theme 1 emerged, “The 
presence of FAERS and Sentinel Initiative improves the vigilance of the public towards 
the adverse effects of drugs and promotes health and public safety.” This theme was 
reflected from the following categories: Patient's health; preventive measure; drug 
manufacture; and, other stakeholders. The first theme was derived from 52 responses. For 
this theme, 52 was the sum of the total responses from the codes where this theme 
emerged from. The second theme showed that, “FAERS and Sentinel Initiative provide a 
systematic data collection for a database that would use health data to improve public 
health.” This theme was reflected from the category of data collection and gathered 28 





this theme emerged from. The third theme showed that, “The reporting model provides a 
regulatory mechanism after the drug approval activities in order to evaluate the medicinal 
products.” This theme was attained from 22 responses. To summarize, the following were 
the themes of the study:  
Theme 1. The FAERS and Sentinel Initiative improve the vigilance of the public 
towards the adverse effects of drugs and promote health and public safety. 
Theme 2. FAERS and Sentinel Initiative provide systematic data collection for a 
database that would use health data to improve public health. 
Theme 3. The reporting model provides a regulatory mechanism after the drug 
approval activities in order to evaluate the medicinal products. 
 The three themes will be further discussed below and codes and categories 
associated with the themes can be found in Appendix E. More comprehensive 
information on the responses of the participants was shown in Appendix D (Emerging 
Codes and Categories).  
Theme 1. The presence of FAERS and Sentinel Initiative improves the vigilance of 
the public towards the adverse effects of drugs and promotes health and public 
safety. 
 Patient’s Health. The maintenance of patient’s health was the priority in every 
surveillance mechanism that promoted the monitoring of the adverse effects of drugs. 
There were some instances where the performance in pharmacovigilance could be 





back the results and effects of a certain drug and medication so that it could be 
comprehensively studied and researched on. As suggested by Participant 15:  
See the benefits can be really big and the reason why I say that if you look 
at the data reporting this not even ten years back I would suggest 5 years 
back for every year you see there are so many challenges and the changes 
that we are coming across in lifestyle and day to day activities which leads 
somewhere towards the pharmaceutical companies and that is where they 
are able to do all this new medications and launch all these drugs but at the 
same time behind the scenes somewhere cumulative data is helping them 
to take the proactive initiative. 
 
The awareness of the people and the patients should be improved in order to increase the 
effectiveness of the Sentinel surveillance system. With the awareness that data could be 
accessed to inquire about certain information on the effects of medication, the patients 
would become proactive in interacting with the doctors. The patients would be more 
informed with the advice that they derive from their physicians. As observed by 
Participant 4: 
So like I told you earlier people were not aware about these portals and 
reporting of various drug problem since it’s a common interaction between 
the doctor and the patient so its take care of the under reporting and all 
these database are linked in sentinel so they will have access to data in 
terms of determining what all adverse reaction can be caused by a drug.  
 
Unexpected adverse effects. The unexpected adverse effects of drugs 
should be reported in order to be prevented. Quoting Participant 12, “There would 
be more clinical information available regarding the adverse effect and what was 
happening so that would be one major benefit.” According to Participant 3, “it 
addresses underreporting; just because somebody had something happened.” 
According to Participant 18, “Benefits are as discussed for FAERS only the 





Threats to public health. According to Participant 2, “I say society it means all 
the players who are responsible for managing healthcare in the system.” The adverse 
effects of drugs pose threats to public health. According to Participant 1, “Then we also 
have issue with health plan if there is like common center dealing with all these 
information.” 
Health safety. According to Participant 1, “it will help them to reduce safety 
issues that what we have and they could help with prescribing activities and it all helps 
the healthcare system in itself.” Participant 2 likewise mentioned, “The potential benefits 
of the patients ultimately the FDA was created to benefit the patients and consumers and 
the larger population will be benefited by this and more genotyping & genomics data.” 
Health safety of patients can be achieved if drugs are safe.  
Patient-centeredness. According to Participant 5, “Sentinel because if the data 
info collected on patients through insurance companies.” Quoting Participant 20, “I think 
it’s mostly patients safety, they are having a lot of information sharing it they are able to 
share it, they are compiling they are getting a great deal more info on all these products 
hopefully to be used for a patient safety.” FAERS and Sentinel Initiative are focused on 
the welfare of patients. 
The FAERS and Sentinel Initiative were forms of surveillance that attempted to 
enance the vigilance of the public towards responsible data collection on the adverse 
effects of drugs. Participant 17 was quick to note the importance of data collection 
because the availability of data was relevant to have durable information which could 





results. The voluntariness of reporting was also a positive factor to ensure that adverse 
drug reactions were protected. The accuracy of the information and the speed of 
obtaining information were some of the benefits that could be derived from Sentinel 
Initiative. As the more proactive surveillance mechanism, Participant 14 said that: 
Benefits will be the speed of obtaining information and the accuracy of the 
information being reported. What I understand from the system, it seems 
that  there is some confusion, chances are that you will have to go to the 
source that has provided the information.Going to the source that has 
provided the information, it will be one or two people; instead of going to 
the whole range of people that are involved even. Even though it’s a new 
way of collecting the AE [adverse events], this might be a speedy process. 
Negative factor- it might be I am not 100 % sure it might have effect 
pharmaceutical companies. 
 
Preventive Measure. The data available using the surveillance methodologies in 
the field of pharmacy should be more inclusive and open to the public. It should be 
emphasized that the main reason behind the data collection of ADRs was to ensure that 
future negative effects would be prevented.  
Preventive action. The reporting model was a form of preventive action to ensure 
that future similar incidents would be prevented. Quoting Participant 13, “I think there 
are may be 18 organizations collecting this data help data warehousing and ensure 
companies like that have access to vast of data and vast of health data.” The purpose of 
Sentinel and FAERS should go beyond mere research. The awareness of the public 
should be increased by making the data available to third parties, thus enhancing the 
vigilance of drug users. As pointed out by Participant 6: 
Since the data is mentioned by those organizations or plans, and at this point only 
FDA is accessing this data, only FDA is approved for accessing the data so it is 
really not true data for drug safety purposes, and FDA using it for the lack of any 





when we have that anybody can access that data space, where anybody can access 
and get information about a potential drug reaction and so on. That day is far 
away. Even after all they say that Sentinel system is augmented FAERS system, 
we still have that challenge out there. 
 
Alerting the public. According to Participant 4, “So like I told you earlier people 
were not aware about these portals and reporting of various drug problems since it’s a 
common interaction between the doctor and the patient.” Participant 17 noted that, “The 
potential challenges which I am looking upon in this under reporting of adverse from 
these methods is to instill a sense of security amongst the patients and we have to educate 
them that their personal data is only used for medicinal and research purposes.” The 
public has the right to know on the possible adverse drug effects based on the experience 
of others. 
Evidence-based. The reporting of adverse drug effects by the patients will allow 
evidence-based conclusions. Quoting Participant 19, “Doctor must have prescribed 
something and there must be some evidence and records they don’t have to wait for many 
years.” 
Vigilance. Participant 16 mentioned that, “I mean all the stakeholders that are 
involved should be responsible whether be the manufacturers or the distributors or the 
FDA or the healthcare professionals or even the patient.” Vigilance in the pharmaceutical 
industry must be improved. Participant 17 was quick to note the importance of data 
collection because the availability of data was relevant to have durable information which 
could help in the advancement of health. 
Drug Manufacturer. The FAERS surveillance system was beneficial in 





Monitoring the adverse reactions added to the information available to the public domain. 
The public and the patients benefit from the surveillance systems. The patients were now 
more informed about the consequences of the medicines that they take. The 
pharmaceutical companies and health agencies also benefitted from the reports. The 
pharmaceutical companies would become more vigilant in ensuring that the products are 
safe. Because of the mechanism to report and self-report the adverse reactions, the 
companies that manufacture drugs would now be more careful in the advancement of the 
safety of the medicine. The use of health data was one of the advantages in the use 
FAERS. Health data that was voluntarily given to the FDA could create an awareness to 
the general public. The availability of the information that could readily be accessed by 
the public was one of the benefits of the FAERS.  
Drug safety. According to Participant 17, “It will help derive the FDA and to 
evaluate about a drug and take some safety measures about a drug.” Drug safety should 
be prioritized in ensuring that there were proper reportorial mechanisms. 
Opportunity to improve healthcare. Quoting Participant 5, “So the challenge 
again would be the lack of partnership, they have to increase their partnership to all 
physicians, pharmacies in order to expand their data base.” Healthcare professionals 
would improve their performance if the drugs were properly regulated.  
Disease occurrence. Disease occurrence could be lessened if there was proper 
regulation of drugs available in the market. Participant 19 noted that, “There are some 
other diseases and other things that I have and if I am going to take this medication it 





Other Stakeholders. The scope of the Sentinel Initiative could be enhanced. 
More stakeholders should be considered. The presence of more stakeholders would make 
the benefits and advantages of the policies more comprehensive and encompassing. The 
awareness of the people about these surveillance systems should be enhanced. The self-
reporting requirements should be more active. More people should be able to access the 
information. The information collected should not be limited for research purposes but 
should actually include having relevance to the general public. 
According to Participant 5, there was a need to obtain more stakeholders to 
improve the performance in the reportorial requirements. It could be said that the 
inclusion of more stakeholders would make the drug companies more proactive because 
more interested parties would be affected by their actions: 
They will need to obtain more stakeholders so I don’t think they have a 
method to handle the under reporting of drug reactions so it doesn’t seem 
that they have a separate method they can use to overcome under reporting 
of worst events so if the data is not there they can obtain any additional 
information. 
 
 Accessibility. Participant 5 noted that, “Consumer may not allow releasing their 
health care info and they need to increase their stakeholders if they want to expand and 
implement all over the country.” A more inclusive progress in the field of 
pharmacovigilance was possible if there were more stakeholders. 
Inclusive. It was noted by Participant 5 that, “To obtain extensive stakeholders 
and partners to participate in this initiative there will have to some kind of method to 





the database.” A more inclusive system should be created so that the development would 
go beyond research purposes. 
Discovery of new risks. New risks on the adverse drug effects would be 
prevented. As mentioned by Participant 4, “That it can eliminate under reporting to extent 
but it will be still be there because the access to data is small and I think they are also 
working on it once data bases are linked and they have access to those databases then 
they will have better analysis to problems of adverse drug reactions.” 
To summarize, it could be concluded that the adverse effects of drugs would be 
recognized and the safety of the patients and the public would be prioritized. The 
presence of FAERS and Sentinel Initiative improved the vigilance of the public towards 
the adverse effects of drugs. A more inclusive database would include other stakeholders 
and make the records more accessible. The availability of a surveillance system such as 
FAERS and Sentinel Initiative would improve drug safety. 
Theme 2. FAERS and Sentinel Initiative provide a systematic data collection for a 
database that would use health data to improve public health. 
The FAERS was beneficial because it was a form of data collection that was 
based on the voluntary reporting of individuals, patients or physicians that suffered from 
ADRs. It was beneficial because the patients voluntarily report the data and not based on 
compulsory requirements mandated by regulations. Further, the FAERS surveillance 
system allowed the pulling out of the market, the drugs that were proven to be 





Data collection. Participant 17 noted that, “The availability of vast volume of data 
which includes not only the drug reaction details but also the information such as medical 
history of the patient, personal details such as age etc. also all this information will help 
us derive relevant and durable information from the data.” FAERS and Sentinel collected 
data from patients regarding the adverse effects of drugs. 
Use of health data. Health data was used for the record of FDA. According to 
Participant 14, “There are various organizations and to be exact I believe 18 
organizations that are involved in retrieving health data.”  
Active system. The Sentinel Initiative was an active system of reporting. As 
observed by Participant 4, “So benefits like I told you that it's an active system they have 
immediate results.” According to Participant 17, “Benefits will be the speed of obtaining 
information, the accuracy of the information being reported and there seem for what I 
understand from the system there seem that if there is some confusion.” 
Voluntary reporting. The voluntariness of reporting was evident in the regulation. 
According to Participant 1, “FAERS is basically everything is voluntarily done most of 
the time it is more specific to particular patients.” According to Participant 6, “All those 
drug adverse reports either directly send to FDA or they are sent by the manufactures to 
FDA are entered in FAERS. The biggest issue here in this whole exercise is that reporting 
a drug adverse reaction is not required by law or anyone else but it’s an voluntary basis 
exercise.” 
Systematic database. Quoting Participant 7, “FAERS is the FDA adverse events 





and medication errors.” Reporting the adverse drug reactions allowed having a present 
systematic database. According to Participant 4, the Sentinel initiative, “That it can 
eliminate under reporting to extent but it will be still be there because the access to data is 
small and I think they are also working on it once data bases are linked and they have 
access to those databases then they will have better analysis to problems of adverse drug 
reactions.” 
Privacy. Privacy of the individuals who reported adverse effects might be at stake. 
According to Participant 6, “I really see here is the privacy issue- the HIPAA compliance. 
I don’t know if the patients would like to share their information to a third party.” 
Participant 5 mentioned that, “Adherence to privacy laws, consumer may not allow to 
release their health care info and they need to increase their stakeholders if they want to 
expand and implement all over the country.” 
Relative assessment. There could be differences in how a person assessed or 
evaluated the effects of drugs. According to Participant 8: 
With the FAERS system addressing adverse differential FAERS is dependent on 
whether the patient really calls FDA or health care company and that one is limited. 
Whereas with Sentinel the patient may be either talking to healthcare profession that I 
had reaction with drug and it might get reported much more better than the FAERS 
system where the patient might even not know where to report. 
 
The Sentinel could be a great help in ensuring that all adverse reactions to a drug were 
reported. It was to be noted that underreporting must be discouraged because failure to 
notify the FDA regarding certain instances may pose danger to the lives of future users of 
the medication. Participant 17 further noted that: 
Sentinel Initiative address uneven quality of adverse drug reactions reports 





the patients report themselves about a serious suspected drug reaction and 
information can be limited so it can be difficult for the FDA to decide 
whether an adverse reaction is serious or not and it can be difficult for the 
FDA to take some safety measures against the drug. 
 
The FAERS surveillance methodology was perceived to be a passive 
methodology. This was contrasted with the capability of the FAERS wherein there was a 
less number of population reached. According to Participant 6, the Sentinel surveillance 
methodology was an improved way of collecting data because it was more active as it 
was highly imposed and regulated:  
Per the latest estimate, there are about 18 organizations participating and 
FDA can access the medical data of almost 178 million patients through 
this initiative. Since the data is maintained by the organizations/plans 
using a common data model, it’s an example of distributed database. This 
system is available to FDA only for monitoring the post-marketing 
product safety information. A query is entered into the system and FDA 
can have the information from this vast data of 178 million patients on 
need basis. Because of the nature of information retrieved from this vast 
data, the Sentinel initiative is so called “active” system. Why I’m calling it 
“Active” because the data is coming from HMOs plans, hospitals, and 
other medical centers where the data is entered by the health care 
professional while they are consulting or treating a patient. So I would say 
that the Sentinel initiative is augmented the FAERS system. 
 
The same participant was of the observation that the Sentinel was better in terms of data 
collection and was a far cry from the passive FAERS system where compliance seemed 
to be optional, “All those drug adverse reports either directly send to FDA or they are 
sent by the manufactures to FDA are entered in FAERS. The biggest issue here in this 
whole exercise is that reporting a drug adverse reaction is not required by law or anyone 
else but it’s an voluntary basis exercise.” 
 To summarize the second theme, it could be inferred that FAERS and Sentinel 





health. Having a systematic mode of data collection would allow the careful sorting of 
what was relevant and what was not. Data collection of adverse drug effects would also 
help in research and prevention of ADRs in the future.  
Theme 3. The reporting model provides a regulatory mechanism after the drug 
approval activities in order to evaluate the medicinal products. 
The FAERS and Sentinel Initiative provided a good regulatory mechanism 
because the FDA would have access to vital information to monitor and evaluate the 
adverse effects of drug products. One of the challenges in FAERS was that it was a mere 
passive way of reporting data to the FDA. Underreporting was prevalent in the FAERS 
system because of the lack of mechanisms to ensure that each ADR is brought to the 
attention of the FDA. According to Participant 7, there are many challenges to the current 
FAERS: 
The current FAERS system doesn’t have a good picture, there is not 
necessarily a good population size and not an easy way to interpret the 
data with the advanced analysis. So for the electronic healthcare data 
source, we will be tracking millions of patients and will also contain more 
comprehensive and complete information for the patients that are in the 
system. We will maximize the efficiency of the risk identification system, 
and also the incidents of reporting will be detectable and accurate. 
 
The access to data in the FAERS system was also a challenge. Scientists of the FDA were 
not able to access the reports reported to FAERS on a real time basis. This posed great 
threats to the safety of the public when the data could not be divulged to the public in a 
prompt manner. As observed by Participant 10: 
As I said earlier, scientists will have capabilities to find the answers to 
some of their questions in weeks, which with the FAERS systems used to 
take months or sometimes even longer, so that’s one of the benefits I see. 





research for 5 years and then figure out okay, this is not going to help. So 
probably getting the right kind of remediation, I don’t have the right word 
but finding right resolutions for particular health problems I think this 
system would help. 
 
Sentinel Initiative and FAERS had challenges and negative impacts because of lack of an 
effective and efficient regulation to ensure that the purpose was served. There was lack of 
responsibility in the implementation and evaluation.The rules should be more specific in 
pointing out the certain responsibilities and accountability of the different government 
agencies such as the FDA. The data collected might not be valuable for the human public 
because it was not accessible. There could be an issue of privacy in the reporting 
requirements. As in other policies, the issue of privacy in the reporting of adverse impacts 
could be a major concern of patients and other affected individuals. 
One disadvantage of the Sentinel Program was the lack of responsibility in the 
implementation and evaluation. There was a system of notification but the liability of the 
drug companies was not clear. There was no system of going to the next step once the 
effects of notifcation had been sent to the FDA. As pointed by Participant 19:  
An international body that‘s like they call it an international conference on 
humanizations and then they came up with the guidelines and that 
guidelines helped us to build that system, the FDA adversary reporting 
system. The one is based on the guidelines and in that FAERS the 
manufacturers is responsible to notify as the drug is out in the market they 
just have to notify the market if there is any event related to that drug.  
 
A challenge posed in the evaluation of the methhods in FDA Sentinel was the fact that 
the data collected might not be collected for research purposes. There was a need to 
ensure that the validity of the coding would be maintained. According to Participant 11, 





because “they need all that information to make the assessment and to approve or 
disapprove you know drugs on the market so they should want to have the best 
surveillance system out there.” The following explained the different codes associated to 
this formed theme: 
Risk evaluation. Participant 13 mentioned that, “I think the challenges are that 
you know with a lot of data you also comes with it is noise and you know the quality of 
data and probably you can have where signals will get lost and then you have different 
interpretations of signals of what is actually a risk and what is I think it gets a little bit 
murky with that large amount of data.” The risks on drugs would properly be assessed if 
there was a proper reporting model.  
Reporting model. Participant 5 noted that, “It doesn’t seem that they have a 
separate method they can use to overcome under reporting of worst events so if the data 
is not there they can obtain any additional information.” The reporting model of how 
adverse drug effects were recorded should be systematic. As mentioned by Participant 17, 
“The sentinel would help make the data more reliable removing the underreporting of 
several adverse drug reactions by it will flood the data with records which people earlier 
used to think may be irrelevant or not necessary and sufficient to be reported.” 
Post-drug approval activities. According to Participant 4, “So basically they use 
all these query methods so that they can query these large database to determine to get the 
desired results of what are on what features are they looking for and what kind of 
problems they want to solve or especially what drug they want to improve.” Post-drug 





Evaluation of products. The proper evaluation of products should be the priority 
in order to ensure health safety. According to Participant 18, “Evaluation is done 
principally by FDA and they will be the one who will analyze the data and gather critical 
information out of this.” Participant 9 mentioned that there could be regional restrictions 
for the study itself because the usage of the drug could be much wider in region than 
compared to other regions. 
Responsibility. There should be a government agency that regulates drugs in order 
to monitor responsibility on the safety of drugs. Participant 20 mentioned, “So here again 
I think the agency has the ultimate responsibility when it comes to reporting though in 
general it is on … it’s on the health care professionals and consumers.” 
The relativity of determining whether a certain effect was adverse or not was a 
consideration that posed challenge to the effectiveness of the Sentinel surveillance policy. 
Participant 9 mentioned that there could be regional restrictions for the study itself 
because the usage of the drug could be much wider in region than compared to other 
regions. The funds were also challenges to the methods of reporting. According to 
Participant 2: 
What you call adverse reaction may not be adverse reaction historically 
the away FDA has taken the stance like sometimes because they are free 
to report it o media they are free to report it to pharma company they are 
free to create out a norm that you to have to pull out the drug from the 
market these are the sensitive thing so its is up to the pharma companies to 
take a stance and really help FDA to understand or keep a list of things I 
am just simplifying things a little bit but these are the risks. 
 
As in any program or policy, the issue of privacy was a big consideration in determining 





of the patients could also be compromised with the new reportorial requirements. Privacy 
concerns were also raised by Participant 5: 
So right now there is limited data source and have 17 partners right now 
and to this be able to work they will have to expand and their data sources 
to a great deal, funding will be another challenge, adherence to privacy 
loss, consumer may not allow to release their health care info and they 
need to increase their stakeholders if they want to expand and implement 
all over the country and internationally as worse event and signal 
collection is worldwide just the USA , right now the sentinel would be 
limited USA. 
 
There was a need to include more organizations to cooperate with the Sentinel Initiative. 
Currently, there were only 18 organizations that were part of this policy. According to 
Participant 12, “So one of the major disadvantages or challenges that have been referred 
to that I see is that there are only 18 organizations that are currently involved so I feel like 
that would limit the sentinel initiative so there need to be more organization that need to 
be involved I feel to deal with this challenge.” There was a need to focus on including 
more organizations so that the data collected by FDA would be more comprehensive and 
the information made available to the public would be more complete and relevant. 
To summarize the third theme, it could be concluded that the presence of a 
reporting model provided a regulatory mechanism after the drug approval activities in 
order to evaluate the medicinal products. A regulatory mechanism would decrease the 
voluntariness of reporting and allow a more systematic way of monitoring the adverse 
drug effects. Further, the regulatory mechanism would hold a specific government 







Responses to the Research Questions 
RQ1. The results of the study answered the three research questions originally 
posed. The first research question asked the prospective benefits of the FDA's Sentinel 
Initiative as compared with the FAERS surveillance methodology. Sentinel Initiative and 
FAERS were beneficial in pharmacovigilance because they monitored the adverse 
reactions to drugs and medication. Monitoring the adverse reactions added to the 
information available to the public domain. The public and the patients benefitted from 
the surveillance systems. The patients were now more informed about the consequences 
of the medicines that they took. The pharmaceutical companies and health agencies also 
benefitted from the reports. The pharmaceutical companies would become more vigilant 
in ensuring that the products were safe. Because of the mechanism to report and self-
report the adverse reactions, the companies that manufacture drugs would now be more 
careful in the advancement of the safety of the medicine.  
The Sentinel could be a great help in ensuring that all adverse reactions to a drug 
were reported. As mentioned by Participant 17, “The sentinel would help make the data 
more reliable removing the underreporting of several adverse drug reactions by it will 
flood the data with records which people earlier used to think may be irrelevant or not 
necessary and sufficient to be reported.” As a more active way of getting information to 
monitor adverse drug effects, Sentinel Initiative promised a more reliable source of data 
available for the public and for pharmaceutical companies. Further, the Sentinel Initiative 





The FAERS surveillance methodology was perceived to be a passive 
methodology. As observed by Participant 9, the capturing of data in Sentinel was more 
proactive and real time data was collected. The same participant was of the observation 
that the Sentinel was better in terms of data collection and was a far cry from the passive 
FAERS system where compliance seemed to be optional, “All those drug adverse reports 
either directly send to FDA or they are sent by the manufactures to FDA are entered in 
FAERS.” In FAERS, it can be said that there was already accountability on the part of 
FDA.  
RQ2. The second research question asked the challenges and negative impacts of 
the FDA's Sentinel Initiative as compared with the FAERS surveillance methodology. 
Sentinel Initiative and FAERS had challenges and negative impacts because of lack of an 
effective and efficient regulation to ensure that the purpose was served. There was lack of 
responsibility in the implementation and evaluation. The rules should be more specific in 
pointing out the certain responsibilities and accountability of the different government 
agencies such as the FDA. The data collected might not be valuable for the human public 
because it was not accessible. There could be an issue of privacy in the reporting 
requirements. As in other policies, the issue of privacy in the reporting of adverse impacts 
could be a major concern of patients and other affected individuals.  
One disadvantage of the Sentinel Program was the lack of responsibility in the 
implementation and evaluation. The relativity of determining whether a certain effect was 
adverse or not, was a consideration that posed challenge to the effectiveness of the 





restrictions for the study itself because the usage of the drug could be much wider in 
region than compared to other regions. 
RQ3. The third research question asked the lessons learned that could enhance the 
scope of the Sentinel Initiative. The scope of the Sentinel Initiative could be enhanced. 
More stakeholders should be considered. The presence of more stakeholders would make 
the benefits and advantages of the policies more comprehensive and encompassing. The 
awareness of the people about these surveillance systems should be enhanced. The self-
reporting requirements should be more active. More people should be able to access the 
information. The information collected should not be limited for research purposes but 
should actually include having relevance to the general public. There were some 
instances where the performance in pharmacovigilance could be improved from the 
current set up of FDA’s Sentinel. There was a possibility of tracking back the results and 
effects of a certain drug and medication so that it could be comprehensively studied and 
researched.  
Inclusion of more stakeholders. The scope of the Sentinel Initiative could be 
enhanced. More stakeholders should be considered. The presence of more stakeholders 
would make the benefits and advantages of the policies more comprehensive and 
encompassing. The awareness of the people about these surveillance systems should be 
enhanced. The self-reporting requirements should be more active. More people should be 
able to access the information. The information collected should not be limited for 





More active self-reporting requirements. The reporting model of how adverse 
drug effects were recorded should be systematic. Post-drug approval activities must be 
evaluated to ensure the safety of the public. The requirements to report must be more 
stringent. The information must be used by the FDA to improve data collection and 
establish a safer method of drug manufacture. As mentioned by Participant 17, “The 
sentinel would help make the data more reliable removing the underreporting of several 
adverse drug reactions by it will flood the data with records which people earlier used to 
think may be irrelevant or not necessary and sufficient to be reported.” 
Summary 
 There were various reasons why FAERS and Sentinel Initiative were effective 
surveillance methodologies to enhance pharmacovigilance. The Sentinel could be a great 
help in ensuring that all adverse reactions to a drug were reported. The availability of the 
information that could readily be accessed by the public was one of the benefits of the 
FAERS. On the other hand, the accuracy of the information and the speed of obtaining 
information were some of the benefits that could be derived from Sentinel Initiative.  
 While there are benefits and advantages, there were also challenges related to the 
implementation of either FAERS or Sentinel Initiative. One disadvantage of the Sentinel 
Program was the lack of responsibility in the implementation and evaluation. There was a 
system of notification but the liability of the drug companies was not clear. A challenge 
posed in the evaluation of the methods in FDA Sentinel was the fact that the data 
collected may not be collected for research purposes. There was a need to ensure that the 





privacy was a big consideration in determining the impact and challenges to a specific 
program. There was a need to include more organizations to cooperate with the Sentinel 
Initiative.  
 There was a need to enhance the scope of Sentinel Initiative to make it a more 
effective way of surveillance for pharmacovigilance. It could be said that the inclusion of 
more stakeholders would make the drug companies more proactive because more 
interested parties would be affected by their actions. The awareness of the people and the 
patients should be improved in order to increase the effectiveness of the Sentinel 
surveillance system. With the awareness that data could be accessed to inquire about 
certain information on the effects of medication, the patients would become proactive in 
interacting with the doctors. The data available using the surveillance methodologies in 
the field of pharmacy should be more inclusive and open to the public. This would ensure 





Chapter 5: Discussion  
 The current FDA consumer safety surveillance system used FAERS for reporting 
adverse events involving pharmaceutical drugs (FDA, 2012a; Powers & Cook, 2012). 
The FAERS used a database designed to assist the FDA and its partners in monitoring 
postmarketing safety of approved drugs and other biologic products (Powers & Cook, 
2012). However, the FAERS had limitations such as not reporting real-time data 
collection (FDA, 2012a). Therefore, the FDA launched the Sentinel Initiative in 2008. 
The FAERS and Sentinel Initiative were adverse drug reaction (ADR) reporting systems. 
This study addressed the lack of research regarding the impact of Sentinel Initiative 
compared to the FAERS. It was necessary to assess the benefits and challenges associated 
with the FDA’s Sentinel Initiative compared to the current FAERS surveillance 
methodology. 
According to the FDA (2012a), the FAERS had (a) a system for reporting the 
adverse effects of drugs, and (b) a database for these reported cases of ADRs.  The 
Sentinel Initiative was a national electronic system for monitoring the safety of FDA-
approved drugs and other medical products (FDA, 2012d). The Sentinel system was 
developed and implemented as an aid to the existing FAERS. The FAERS did not make 
use of real-time data, which referred to the precise time or location that a drug was used 
or consumed by the market members (Gottlieb, 2005). Presently, the reporting system 
used by the FAERS was voluntary and quarterly (Powers & Cook, 2012). Instead of 





existing data systems such as electronic health record systems and medical claims 
databases (Platt et al., 2009).  
The purpose of this qualitative comparative case study was to examine the 
FAERS surveillance system and the FDA’s Sentinel Initiative to determine the benefits 
and consequences of the Sentinel Initiative in terms of drug consumer safety. This 
qualitative study included the perceptions of individuals who had worked closely with 
FAERS program and were aware of the Sentinel Initiative. I interviewed key informants 
who worked with FAERS andwere familiar with the Sentinel Initiative to better 
understand their perceptions of the differences between these two programs.  
The results of the study answered the three research questions originally posed. 
The first research question addressed the prospective benefits of the FDA’s Sentinel 
Initiative as compared with the FAERS surveillance methodology. Both programs were 
beneficial in pharmacovigilance because they monitor the adverse reactions to drugs and 
medication. However, I found that the Sentinel system could be a great help in ensuring 
that all adverse reactions to a drug were reported. Participants also described the FAERS 
surveillance system as a passive methodology. One participant pointed out that the 
Sentinel was better in terms of data collection and was superior to the passive FAERS 
system in which compliance seemed to be optional. Participants reported that the FDA’s 
Sentinel Initiative was better than the FAERS surveillance methodology. wasThe results 
of this study provided information regarding the effectiveness of the FAERS and the 
Sentinel Initiative. No current study compares experts’ perceptions of the FDA’s Sentinel 





The second research question addressed the challenges and negative impacts of 
the FDA’s Sentinel Initiative as compared with the FAERS surveillance methodology. 
Both programs had challenges and negative impacts because of lack of effective and 
efficient regulation to ensure that the purpose of the two systems is served. There is also 
an issue of privacy in the reporting requirements.  One disadvantage of the FAERS 
surveillance methodology is not being able to use real-time data. One disadvantage of the 
Sentinel program was the lack of responsibility in implementation and evaluation of data 
collected through the Sentinel. The relativity of determining whether a certain effect was 
adverse or not, it was a challenge to the effectiveness of the Sentinel surveillance policy. 
Both programs had advantages and disadvantages. The FAERS surveillance methodology 
was seen as a weaker methodology because it could not use real-time data and had a 
small database compared to the Sentinel surveillance. However, there was lack of 
accountability in the implementation and evaluation of the Sentinel Program. 
 It was important to determine the advantages of the Sentinel Initiative because 
insights from this study could support the FDA’s efforts to improve reporting systems to 
detect ADR. Robb (2012) described the advantages of the Sentinel program such as using 
voluntary participants to have an active safety surveillance system. Moreover, within 2 
years of its existence, the Mini-Sentinel program had 31 academic and private 
organizations associated with it (Platt et al., 2012). Additionally, Forrow et al. (2012) 
asserted that the Mini-Sentinel program is remarkable because it had its own 





The third research question addressed the lessons learned that could enhance the 
scope of the Sentinel Initiative. The study indicated that the scope of the Sentinel 
Initiative could be enhanced; however, more stakeholders should be considered to make 
the advantages of the policies more comprehensive and encompassing. Awareness of 
these programs should also be improved so that more individuals would be able to access 
the information. No study had been conducted to examine the changes that should be 
made to the Sentinel Initiative for it to improve. 
In this chapter, the results of the study were interpreted and the implications of the 
findings were explained. The study limitations were also described and future research 
recommendation was also provided. The chapter is concluded with the summary. 
Interpretation of the Findings 
Theme 1. The presence of FAERS and Sentinel Initiative improves the vigilance 
of the public towards the adverse effects of drugs and promotes health and public safety. 
Three themes emerged from the data analysis. First, the presence of FAERS and Sentinel 
Initiative improves the vigilance of the public regarding the adverse effects of drugs and 
promotes health and public safety. Second, the FAERS and Sentinel Initiative provide 
systematic data collection for a database that uses health data to improve public health. 
Third, the reporting model provides a regulatory mechanism after the drug approval 
activities in order to evaluate the medicinal products. 
Theme 1 





The first finding is that the presence of FAERS and Sentinel Initiative improves 
the vigilance of the public regarding the adverse effects of drugs and promotes health and 
public safety. This theme was derived from the following categories: data collection, 
patient’s health, regulatory mechanism, preventive measure, other stakeholders, and drug 
manufacturer. In relation to the problem statement, the results indicated that both 
programs had advantages and disadvantages. The participants confirmed that both 
programs had the ability to make individuals vigilant about adverse effects of drugs. 
However, the participants emphasized that the Sentinel Initiative was better because it 
used an active system of reporting that brought immediate results. Moreover, the Sentinel 
Initiative was better when it came to relative assessment of patients because the patient 
might talk to an experienced health care professional, which is better than the FAERS 
system in which the patient might not know where to report.  
This finding confirmed existing literature about ADRs. Both the FAERS and 
Sentinel Initiative improved pharmacovigilance of the public regarding the adverse 
effects of drugs and promoted health and public safety. Behrman et al. (2011) stated that 
the FDA Sentinel Initiative served as an additional tool for the FDA to evaluate the safety 
of medical products and acted as a national resource for the FDA to take advantage of 
investigating medical product performance. Additionally, the Sentinel Initiative would 
become a national resource of a learning health care system. The Sentinel Initiative 
enhances existing health care information to allow the FDA to perform active post-
market safety surveillance in support of the current surveillance systems had(Robb et al., 





could also be complementary to the evaluation of FAERS reports. Henceforth, it showed 
there were many methods of reporting of adverse events were evaluated by stakeholders 
than just simply relying on the FAERS. 
Using FAERS and the Sentinel Initiative, the FDA can scrutinize regulated 
medical products nearly as fast as real time to better comprehend product safety (Robb et 
al., 2012). The Sentinel Initiative aided the FDA in discovering and analyzing post-
market safety signals through signal generation, signal refinement, and signal evaluation, 
which referred to the concern over an excess of irregular and negative events when 
compared to what was traditionally associated with a product’s use (Robb et al., 2012).  
Moreover, the Sentinel Initiative was helpful to the FDA in making regulatory decisions 
(Robb et al., 2012).   
Several researchers supported the use of the Sentinel Initiative through the Mini-
Sentinel program. The Mini-Sentinel program was a pilot under the FDA Sentinel 
initiative, as an effort to implement a national system that would assess the safety of 
medical products. Mini-Sentinel was successful in serving as a general-purpose vaccine 
safety monitoring system (Robb et al., 2012). Platt et al. (2012) found that the Mini-
Sentinel program employed various activities such as robust surveillance of a wide range 
of drugs and vaccines, as well as improving the common data model to secure additional 
types of data. According to Forrow et al. (2012), the Mini-Sentinel program was 
remarkable because it had its own organizational structure as well as principles that 
regulated its operations. These policies and structures allowed it to influence the structure 





In the context of the theoretical framework, this finding is consistent with theory 
of preemption, which asserts that it was important to use information to make sound 
judgments regarding issues or activities of national importance, such as prescription drug-
related regulations. The existence of FAERS and Sentinel Initiative provide current, 
accurate, and actionable information to the FDA to ensure consumer safety, especially in 
detecting uncommon cases of product exposures (Platt et al., 2009). 
Due to the FAERS and Sentinel Initiative, adverse effects of drugs would be 
recognized and the safety of the patients and the public would be prioritized. As a result 
of the FAERS and Sentinel Initiative, the public will become more vigilant regarding the 
adverse effects of drugs. Thus, the FAERS and Sentinel Initiative would improve drug 
safety and public health as both systems complements each other for adverse event 
reporting. The patients’ safety is enhanced due to existence of both the methods in place.  
Theme 2 
The second finding was that FAERS and Sentinel Initiative provided a systematic 
data collection for a database that would use health data to improve public health. 
Systematic data collection was included in pharmacovigilance. Pharmacovigilance 
activities encompassed the collecting, exchanging, accumulating, analyzing, 
interpretation, and sharing of data regarding the experiences of patients who had used a 
specific drug or certain therapeutic agent (van Grootheest & Richesson, 2012). In relation 
to the problem statement, study findings indicated that both programs provide systematic 
data collection for a database. One of the problems in this study was to determine 





of the information and the speed of obtaining information were some of the benefits that 
could be derived from the Sentinel Initiative. The Sentinel surveillance methodology was 
an improved way of collecting data because it was more active as it was highly imposed 
and regulated. Moreover, the Sentinel Initiative could be a great help in ensuring that all 
adverse reactions to a drug were reported. Moore, Furberg, Mattison, and Cohen (2016) 
concluded that Sentinel surveillance methodology was a better way to collect data to 
assess adverse drug events reported to the FDA. 
This finding confirmed existing literature about the importance of having 
systematic data collection. Researchers emphasized the importance of systematic 
detection and assessment practices that could handle adverse drug effects (van Grootheest 
& Richesson, 2012). Hoffman, Overstreet, and Doraiswamy (2013) stated that more than 
770,000 injuries or deaths annually could be attributed to adverse events linked to drugs 
already approved by the FDA. Hoffman et al. stated that approximately 28% of these 
adverse events could be prevented if there was an effective computerized monitoring 
system in place. Through systematic data collection, thousands of individuals could be 
saved from the side effects of the drugs they used before a clinician could be subjected to 
public investigation and action (van Grootheest & Richesson, 2012). FAERS had the 
ability to acquire 700,000 reported adverse events annually across different therapeutic 
categories, making it a powerful database (Hoffman et al., 2013). 
Systematic data collection was also important for adverse drug reactions (van 
Grootheest & Richesson, 2012). If an adverse drug reaction was suspected, then trials and 





carried out, careful and systematic collection of data was necessary (van Grootheest & 
Richesson, 2012). 
The case of banning thalidomide from the market was the result of systematic 
data collection (van Grootheest & Richesson, 2012). The case propelled the FDA to start 
a systematic collection of ADR reports to identify drugs that would harm individuals. 
Other countries followed suit and developed new rules and regulations that organizations 
needed to adhere to before releasing a new drug in the market. 
In the context of the theoretical framework, this finding was consistent with the 
theory of preemption, which is applied in the analysis of useddata to make market-based 
decisions regarding drug safety (Gostin, 2011). The theory of preemption also involves 
using data from ADRs and cases to address the damages experienced by affected 
consumers (Valoir & Ghosh, 2011). Thus, systematic data collection was needed to 
protect the health of the public.  
The FAERS and Sentinel Initiative provided a systematic database that 
professionals and experts can use to improve public health. A systematic mode of data 
collection would filter what was relevant and what was not. Data collection of adverse 
drug effects would help in research and prevention of ADRs in the future. Moreover, 
reduction of ADRs could save thousands of lives. 
Theme 3  
The third finding was that the reporting model provided a regulatory mechanism 
after the drug approval activities in order to evaluate the medicinal products. One of the 





the FDA. In fact, reporting could be optional. Moreover, the reports sent to FAERS could 
not be accessed on a real-time basis. This was a threat to the safety of the public when 
important health data could not be divulged to the public in a prompt manner.  Both the 
FAERS and the Sentinel Initiative could be improved through responsible 
implementation and evaluation.  
This finding extended existing literature about the importance of having a 
reporting model. The main motivation behind reporting models was to ensure public 
safety and the main strategy was still population monitoring (van Grootheest & 
Richesson, 2012). Reporting model was included in pharmacovigilance. Reporting 
models were important because in pharmacovigilance, there was an assumption that all 
therapeutic agents had a specific level of risks and these risks were not equally distributed 
across the population. Thus, some groups were more likely to suffer from ADRs 
compared to others (van Grootheest & Richesson, 2012). It was important to monitor and 
to warn individuals of the possible side effects or adverse effects of the drug. Raine 
(2012) emphasized that harmful effects from drugs should be monitored, as they could be 
deadly and costly to the healthcare sector. Raine asserted that costs of adverse effects of 
drugs could be greater in developing countries than in developed countries. Adverse 
incidents might have a negative impact to the credibility and success of important public 
health programs (Raine, 2012). In order to improve pharmacovigilance strategies, WHO 
also asserted that there should be efficient and effective planning and implementing of 





In the context of the theoretical framework, this finding was consistent with 
theory of preemption. The theory asserts the significance of data in make sound judgment 
regarding issues or activities of national importance such as public health. A reporting 
model was important because it provided a regulatory mechanism after the drug approval 
activities in order to evaluate the medicinal products. A reporting model should be 
developed because it would help in the systematic collection of data regarding adverse 
drug effects. Moreover, a specific government agency might be held accountable for the 
evaluation of the effects of drugs.  
Limitations of the Study 
There were many limitations in this study such as researcher bias, sample size, 
instrument, and data collection bias. Each limitation had an impact on this study and 
every effort was done to control the effects of the limitations. One such limitation of this 
study was researcher’s bias. The researcher had extensive knowledge of ADRs and 
pharmacovigilance systems. In order to mitigate this bias, the researcher took data 
collected during participant interviews as is and conducted member checks to ensure that 
the interpretations made were consistent with the actual interpretations intended by the 
participants. This limitation might have an effect on the interview guide/questions used 
for data collection. Recognizing this, the interview guide/questions were written without 
bias and to allow the participants to use their experiences and knowledge to answer the 
questions. 
Another limitation was the sample size. There was the possibility of not obtaining 





had self-reported knowledge or expertise in assessing consumer impact. However, the 
study got enough participation from the sample group. The study was also limited to aim 
for 20 participants with the consideration of data saturation. The limited sample size 
indicated that the findings of the study might not be generalizable. 
Another factor that may result to inadequate results was poorly developed 
interview questions. The interview guide was developed properly to be open-ended, 
specific enough to avoid confusion, and be easy to understand. To avoid this pitfall, great 
care was applied in development of the interview guide.  
Another limitation was the research methodology chosen. However, qualitative 
design was appropriate because existing research in the area is limited. Qualitative 
methodology allowed for rich description of the phenomenon. 
Recommendations for Future Research 
 First, future researchers could extend the study to include not only the key 
informants but also the consumers as well. Perception of the consumers regarding the 
surveillance systems could also aid in development of policies and programs to improve 
them. Moreover, perspectives of the consumer were significant since the consumers 
would be the one who would experience the adverse drug effects. 
 Second, future researchers could also think of other factors that could influence 
the effectiveness of the two programs. Most consumers were hesitant to report adverse 





 Third, future researchers could use a different measurement or data collection 
tool. Data from the two programs could be used to determine whether health data in the 
program actually improved public health. Moreover, documents could also be examined. 
Lastly, future researchers could use quantitative methodology or mixed methods. 
Quantitative methodology allows for collecting data from a large sample size. The size of 
sample size in quantitative studies could mean that it was representative of the whole 
population.  
Implications of the Findings 
 The findings of this study had potential impact for positive change at the societal 
level, organizational level, and individual level. At the individual level, individuals were 
more vigilant about adverse effects of drugs and aware that they should report adverse 
effects. At the organizational level, manufacturers of drugs would be informed of the 
adverse effects of their drugs. Perhaps, the manufacturers could develop new drugs with 
less possibility of adverse effects. At the societal level, policies about drug safety would 
be modified to benefit the public.  
 The findings of the study were consistent with the theory of preemption. The 
theory asserts the importance of using information to make sound judgment about 
national issues like public healht and drug-related regulations (Deftos, 2008; Glantz & 
Annas, 2008). The three findings indicated that information about adverse drug effects 






 The findings of this study helped advanced research methodology in the field of 
pharmacovigilance. The findings of this study revealed perceptions about effectiveness 
and limitations of FAERS and the Sentinel Initiative. The findings of this study indicated 
that qualitative methodology was also effective in comparing the benefits and challenges 
of surveillance methodology associated with FDA’s Sentinel Initiative compared to 
FAERS. The findings of the study also added to the current research base regarding 
pharmacovigilance systems. 
 Ultimately, the results of the study increased awareness of advantages and 
disadvantages of the FAERS and the Sentinel Initiative. Information from the data 
provided information regarding the effectiveness of the FAERS and the Sentinel 
Initiative. At this point, the Sentinel Initiative complements the FAERS system and it 
does not replace FAERS system as it currently stands. The Sentinel Initiative only aims 
to provide additional information on adverse drug events. The results of the study could 
increase the public knowledge of the reporting systems used by the FDA to control 
ADRs.  
 The insights from this study could support the FDA’s efforts to improve reporting 
systems effectiveness to detect ADRs. The benefits and challenges of both FAERS and 
the Sentinel systems found in this study could serve to be foundations for further 
improvements to the programs. The presence of FAERS and Sentinel Initiative improved 
the vigilance of the public towards the adverse effects of drugs. Availability of FAERS 
and Sentinel Initiative also improved drug safety. FAERS and Sentinel Initiative provided 





health. As such, they must also be improved. Improvement of these programs would lead 
to improvement of health and quality of life of the public because challenges of the 
programs on ADR generation would be identified for ease of addressing them. 
Remove this blank line. 
Social Significance  
 This research definitely had potential to increase awareness of advantages and 
disadvantages of the FAERS and the Sentinel Initiative. It was expected that the data 
would provide information regarding the effectiveness of the FAERS and the Sentinel 
Initiative. This study would increase the public knowledge of the reporting systems used 
by the FDA to control ADRs. The lessons learned from this study could support the 
FDA’s efforts to improve reporting systems effectiveness to detect ADRs. This research 
would also add to the research base regarding pharmacovigilance systems.  Moreover, 
with the findings of the study, the benefits and challenges of both FAERS and the 
Sentinel systems would determine that would serve as basis for further improvements to 
the programs. Through this, health and quality of life of consumers would be improved 
because the challenges of the programs on ADR generation would be identified for ease 
of addressing them. As a result, safer medications would be available in the market for 
consumers due to availability of huge safety data through the sentinel system which 
would improve health and quality of life for patients. 
The findings of this study helped in providing support for surveillance systems 
such as FAERS and Sentinel Initiative.  These systems monitored the adverse reactions to 





available to the public domain.  Both the public and the patients benefitted from the 
surveillance systems.  Due to these systems, thousands of lives of people were saved.  
This chapter concludes the study. 
Remove this blank line. 
Summary and Conclusions 
Occurrence of ADRs in the U.S. have increased in the past decade. ADRs were 
costly and had a negative impact on public health programs (Yadav, 2009). Moreover, 
ADRs were among the leading causes of death in many countries, including the United 
States.  From 2004 to 2012, men and women both reported 60,000 deaths due to ADRs 
(Keating & Millman, 2014). Pharmacovigilance systems such as FAERS and Sentinel 
Initiative were used to detect and prevent ADRs. The purpose of this comparative case 
study of the FDA Adverse Events Reporting System (FAERS) surveillance system and 
the FDA's Sentinel Initiative was to determine the benefits and consequences of the 
Sentinel Initiative in terms of drug consumer’s safety.  
The theory of preemption assumes that it is important to use information to make 
sound judgment regarding issues or activities of national importance, such as prescription 
drug-related regulations, require uniform federal regulation, which cannot be provided by 
states (Deftos, 2008; Glantz & Annas, 2008). Given this assumption together with the 
existing literature, it was expected that there will be differences with FAERS and Sentinel 
Initiative programs and that it promoted pharmacovigilance activities. 





 Theme 1. The presence of FAERS and Sentinel Initiative improved the 
vigilance of the public towards the adverse effects of drugs and promotes 
health and public safety. 
 Theme 2. FAERS and Sentinel Initiative provided a systematic data collection 
for a database that would use health data to improve public health. 
 Theme 3. The reporting model provided a regulatory mechanism after the 
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Appendix A: Invitation Letter 
Dear ______________: 
Good day! 
My name is Sonia Batra.  I am a doctoral student at Walden University’s PhD Public 
Health program.  I am currently conducting my dissertation research on the use of the 
FDA Adverse Events Reporting System (FAERS) and the Sentinel Initiative in an effort 
to compare the two and determine the benefits and challenges associated to these said 
programs. You are seleceted to participate in the study because you are identified as a  
subject matter expert in the field of pharmacovigilance and are familiar with FDA 
Adverse Event Reporting System (FAERS) and the FDA sentinel initiative.  I would like 
to invite you to participate in a key informant interview that will last approximately 45 
minutes.  The information that you can provide will be helpful in fulfilling the purpose 
and significance of this study, and help improve the current state of pharmacovigilance 
systems in the country.  
Please be informed that your participation is protected under the ethical rules and 
considerations imposed by the IRB to ensure that you are aware of your rights as 
participants to this study. Please also note you will not receive any payment (thank you 
gifts, compensation, or reimbursement (for travel costs, etc.)) for participating in the 
research study.  Should you wish to participate in this study, you may reply to signify 
your interest to participate.  I will then send you a copy of the informed consent, which 





decision to participate. Additionally, the informed consent may be returned to me in 
person if we are having face to face interview. 
Thank you very much. 
Sincerely, 














Although there may be no direct benefits to you, the possible benefits of your 
participation in the research are to identify benefits and challenges associated with 
FAERS and the Sentinel Initiative to serve as basis for improvement of the programs. 
NEW INFORMATION 
 
If the researcher finds new information during the study, the information would 
be shared with you and you will have an option to change your decision about 
participating.  
The purposes of this form are to provide you, as the potential participant of this study, with 
the relevant information that may affect your decision as to whether or not to participate in 
this research and to record the consent of those who agree to be involved in the study. 
You are seleceted to participate in the study because you are identified as a  subject matter 
expert in the field of pharmacovigilance and are familiar with FDA Adverse Event 
Reporting System (FAERS). 
STUDY PURPOSE 
 
The purpose of the present study of the FAERS surveillance system and the FDA's 
Sentinel Initiative is to determine the benefits and consequences of the Sentinel Initiative in 
terms of drug consumer safety. 
DESCRIPTION OF RESEARCH STUDY 
 
If you decide to participate, you will join a study involving telephone/face to face  
interviews which will be recoded. If you say YES, then your participation will last for 







All information obtained in this study is strictly confidential. The results of this 
research study may be used in reports, presentations, and publications, but the researcher 
will not identify you. In order to maintain confidentiality of your records, Sonia Batra 
will use pseudonyms to replace the name or identification of each subject. Any paper 
copies will be kept in a locked cabinet and electronic formats will be protected by a 
password. Once the study is completed and accepted by Walden University, all digital 




Participation in this study is completely voluntary. It is ok for you to say no, and 
you will not incur any consequences for it. Even if you say yes now, you are still free to 
say no later, and withdraw from the study at any time. If you should withdraw from the 
study, any digital recordings will be deleted. 
 
Please also note you will not receive any payment (thank you gifts, compensation, 




Any questions you have concerning the research study or your participation in the study, 
before or after your consent, will be answered by Sonia Batra. 
 
This form explains the nature, demands, benefits and any risk of the project. By signing 
this form, you agree knowingly to assume any risks involved. Remember, your 
participation is voluntary. You may choose not to participate or to withdraw your consent 
and discontinue participation at any time without penalty or loss of benefit. In signing 
this consent form, you are not waiving any legal claims, rights, or remedies. A copy of 
this consent form will be given (offered) to you. 
 
Please feel free to contact me at xxx-xxx-xxxx for concerns regarding the interview or if 
you have any other questions regarding the study. My email address is Xxxx@xxxx.com. 
 
You can also contact Walden university’s Research Participant Advocate (USA number 
001-612-312-1210 or email address irb@waldenu.edu) if you have any question 







Your signature below indicates that you consent to participate in the above study 
 
___________________________ _________________________ ____________ 





Appendix C. Interview Guide 
Introduction 
- Greet participant.  Introduce the study and its purpose 
The interview is being conducted to determine the benefits and consequences of the 
Sentinel Initiative in terms of drug consumer safety. This is a qualitative study focusing 
on your perceptions beause you have worked closely with FAERS program and are aware 
of the Sentinel Initiative. 
- Review Informed Consent 
- Provide flow of the interview 
Below are the semi-structured interview questions that will be asked during the interview: 
1. How does the Sentinel Initiative improve data gathering of adverse drug reactions 
compared to FAERS? 
a. What are the methods does the Sentinel Initiative use to improve data 
gathering of adverse drug reactions compared to FAERS? 
b. Who is responsible to implement and evaluate such methods? 
c. What are potential challenges or risks that you perceive from these 
methods? 
i. Why? 
ii. Can you tell me more about that? 
d. What are potential benefits from these methods? 
i. Why? 
ii. Can you tell me more about that? 
2. How does the Sentinel Initiative address underreporting of adverse drug reactions 





a. What are the methods that the Sentinel Initiative uses to address 
underreporting of adverse drug reactions compared to FAERS? 
b. Who is responsible to implement and evaluate such methods? 
c. What are potential challenges from these methods? 
i. Why? 
ii. Can you tell me more about that? 
d. What are potential benefits from these methods? 
i. Why? 
ii. Can you tell me more about that? 
3. How does the Sentinel Initiative address differential reporting of adverse drug 
reactions compared to FAERS? 
a. What are the methods for the Sentinel Initiative uses to address differential 
reporting of adverse drug reactions compared to FAERS? 
b. Who is responsible to implement and evaluate such methods? 
c. What are potential challenges from these methods? 
i. Why? 
ii. Can you tell me more about that? 
d. What are potential benefits from these methods? 
i. Why? 
ii. Can you tell me more about that? 
4. How does the Sentinel Initiative address uneven quality of adverse drug reactions 
reports compared to FAERS? 
a. What does the Sentinel Initiative address uneven quality of adverse drug 
reactions compared to FAERS? 





c. What are potential challenges from these methods? 
i. Why? 
ii. Can you tell me more about that? 
d. What are potential benefits from these methods? 
i. Why? 
ii. Can you tell me more about that? 
 
5. What are the possible strategies that limit the disadvantages/challenges of the 
Sentinel Initiative in terms of its impact users? 
a. Who is responsible to implement and evaluate such strategies? 
b. What are potential challenges from such strategies? 
c. What are potential challenges from these methods? 
i. Why? 
ii. Can you tell me more about that? 
d. What are potential benefits from these methods? 
i. Why? 
ii. Can you tell me more about that? 
e. Is there anything else you want to tell me about ADR surveillance?  
i. Why? 
ii. Can you tell me more about that? 
f. Can you recommend another key informant who may be interested in 
participating in my study? 
i. Why? 





Appendix D. Emerging Codes 
Code Meaning Quotes from Participants- Supporting 
Code  
Data collection FAERS and Sentinel 
collect data from 
patients regarding the 
adverse effects of 
drugs. 
The availability of vast volume of data 
which includes not only the drug 
reaction details but also the information 
such as medical history of the patient, 
personal details such as age etc. also all 
this information will help us derive 
relevant and durable information from 
the data. (Participant 17) 
Use of health data Health data is used for 
the record of FDA. 
There are various organizations and to 
be exact I believe 18 organizations that 
are involved in retrieving health data. 
(Participant14) 
Active system The Sentinel Initiative 
is an active system of 
reporting.  
So benefits like I told you that it's an 
active system they have immediate 
results. (Participant 4) 
Voluntary reporting The voluntariness of 
reporting is evident in 
the regulation.  
FAERS is basically everything is 
voluntarily done most of the time it is 
more specific to particular patients. 
(Participant 1) 
Systematic database Reporting the adverse 
drug reactions allow 
having a present 
systematic database.  
FAERS is the FDA adverse events 
reporting system. It’s a database that 
contains the information on Adverse 
events (AE’s) and medication errors. 
(Participant 7) 
Privacy Privacy of the 
individuals who report 
adverse effects might 
be at stake.  
I really see here is the privacy issue. 
The HIPAA compliance. I don’t know if 
the patients would like to share their 
information to a third party. (Participant 
6) 
Relative assessment There can be 
differences in how a 
person assesses or 
evaluates the effects of 
drugs.  
With the FAERS system addressing 
adverse differential FAERS is 
dependent on whether the patient really 
calls FDA or health care company and 
that one is limited. Whereas with 
Sentinel the patient may be either 
talking to healthcare profession that I 
had reaction with drug and it might get 
reported much more better than the 
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adverse effects of 
drugs should be 
reported in order to be 
prevented.  
There would be more clinical 
information available regarding the 
adverse effect and what was happening 
so that would be one major benefit. 
(Participant 12) 
Threats to public 
health 
The adverse effects of 
drugs pose threats to 
public health. 
I say society it means all the players 
who are responsible for managing 
healthcare in the system. (Participant 2) 
Health safety Health safety of 
patients can be 
achieved if drugs are 
safe.  
The potential benefits of the patients 
ultimately the FDA was created to 
benefit the patients and consumers and 
the larger population will be benefited 
by this and more genotyping & 
genomics data. (Participant 2) 
Patient-centeredness FAERS and Sentinel 
Initiative are focused 
on the welfare of 
patients.  
I think it’s mostly patients safety, they 
are having a lot of information sharing it 
they are able to share it, they are 
compiling they are getting a great deal 
more info on all these products 





occurrences on patients 
that do not have direct 
correlation to the drugs 
might be mistaken as 
adverse drug effects. 
I can confirm it if you like all the 
adverse reactions that happened whether 
it was on doctors clinic or it happened 
anywhere else in the hospital  only 6-
10% were reported since the institution 
established FAERS whereas the sentinel 
program because it is not asking you 
report anything it is asking you to just 
keep your data in a particular format 
(Participant 2)  
Risk evaluation The risks on drugs will 
properly be assessed if 
there is a proper 
reporting model.  
I think the challenges are that you know 
with a lot of data you also comes with it 
is noise and you know the quality of 
data and probably you can have where 
signals will get lost and then you have 
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what is actually a risk and what is I 
think it gets a little bit murky with that 
large amount of data (Participant). 
Reporting model The reporting model of 
how adverse drug 
effects are recorded 
should be systematic. 
It doesn’t seem that they have a separate 
method they can use to overcome under 
reporting of worst events so if the data 
is not there they can obtain any 




activities must be 
evaluated to ensure the 
safety of the public. 
So basically they use all these query 
methods so that they can query these 
large database to determine to get the 
desired results of what are on what 
features are they looking for and what 
kind of problems they want to solve or 
especially what drug they want to 
improve. (Participant 4) 
Evaluation of 
products 
The proper evaluation 
of products should be 
the priority in order to 
ensure health safety. 
Evaluation is done principally by FDA 
and they will be the one who will 
analyze the data and gather critical 
information out of this. (Participant 18) 
Responsibility There should be a 
government agency 
that regulates drugs in 
order to monitor 
responsibility on the 
safety of drugs. 
So here again I think the agency has the 
ultimate responsibility when it comes to 
reporting though in general it is on … 
it’s on the health care professionals and 
consumers. (Participant 20) 
Accountability There should be a 
government agency 
that regulates drugs in 
order to monitor 
accountability on the 
safety of drugs. 
Again the FDA, the stakeholders are 
solely responsible for implementing and 
evaluating these methods. (Participant 
17) 
 
Preventive action The reporting model is 
a form of preventive 
action to ensure that 
future similar incidents 
will be prevented. 
I think there are may be 18 
organizations collecting this data help 
data warehousing and ensure companies 
like that have access to vast of data and 
vast of health data. (Participant 13) 
Alerting the public The public has the 
right to know on the 
possible adverse drug 
The potential challenges which I am 
looking upon in this under reporting  of 
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effects based on the 
experience of others. 
a sense of security amongst the patients 
and we have to educate them that their 
personal  data is only used for medicinal 
and research purposes. (Participant 17) 
Evidence-based The reporting of 
adverse drug effects by 
the patients will allow 
evidence-based 
conclusions. 
Doctor must have prescribed something 
and there must be some evidence and 
records they don’t have to wait for 
many years. (Participant 19) 
Vigilance Vigilance in the 
pharmaceutical 
industry must be 
improved. 
I mean all the stake holders that are 
involved should be responsible whether 
be the manufacturers or the distributors 
or the FDA or the healthcare 
professionals or even the patient. 
(Participant 16) 
Accessibility The records and data 
collected should be 
made accessible to the 
public. 
Information is generally documented 
within the healthcare providers database 
it’s more readily accessible to FDA to 
perform to better evaluate the data. 
(Participant 16) 
 
Inclusive A more inclusive 
system should be 
created so that the 
development will go 
beyond research 
purposes. 
To obtain extensive stakeholders and 
partners to participate in this imitative 
there will have to some kind of method 
to educate consumer for this work so 
that they may be able to share their 
health care info to the database. 
(Participant 5) 
Discovery of new 
risks 
New risks on the 
adverse drug effects 
will be prevented. 
That it can eliminate under reporting to 
extent but it will be still be there 
because the access to data is small and I 
think they are also working on it once 
data bases are linked and they have 
access to those databases then  they will 
have better analysis to problems of 
adverse drug reactions. (Participant 4) 
Other stakeholders A more inclusive 
progress in the field of 
pharmacovigilance is 
possible if there are 
more stakeholders. 
Consumer may not allow releasing their 
health care info and they need to 
increase their stakeholders if they want 
to expand and implement all over the 
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Drug safety Drug safety should be 
prioritized in ensuring 
that there are proper 
reportorial 
mechanisms. 
It will help derive the FDA and to 
evaluate about a drug and take some 








performance if the 
drugs are properly 
regulated.  
So the challenge again would be the 
lack of partnership, they have to 
increase their partnership to all 
physicians, pharmacies in order to 
expand their data base. (Participant 5) 
Disease occurrence Disease occurrence can 
be lessened if there is 
proper regulation of 
drugs available in the 
market. 
There are some other diseases and other 
things that I have and if I am going to 
take this medication it going to have an 


















Appendix E. Emerging Themes  
Themes Total No. of 
Responses 
Associated Codes and Categories 
Theme 1. The presence of FAERS 
and Sentinel Initiative improves 
the vigilance of the public 
towards the adverse effects of 
drugs and promotes health and 
public safety. 
 
52 Patient’s Health (Total: 15) 
Unexpected adverse effects (4) 
Threats to public health (4) 
Patient-centeredness (3) 
Health safety (2) 
Coincidental occurrences (2) 
Preventive Measure (Total: 12) 
Vigilance (4) 
Preventive action (3) 
Alerting the public (3) 
Evidence-based (2) 
 
Drug Manufacture (Total: 12) 
Drug safety (6) 
Opportunity to improve healthcare 
(3) professionals 
Disease occurrence (3) 
Other Stakeholders (Total: 13) 
Other stakeholders (5) 
Accessibility (3) 
Inclusive (3) 
Discovery of new risks (2) 
 
Theme 2. FAERS and Sentinel 
Initiative provide a systematic 
data collection for a database that 
would use health data to improve 
public health. 
28 Data Collection (Total: 28) 
Systematic database (7) 
Privacy (4) 
Voluntary reporting (4) 
Data collection (4) 
Active system (4) 
Use of health data (3) 
Relative assessment (2) 
 
Theme 3. The reporting model 
provides a regulatory mechanism 
after the drug approval activities 
in order to evaluate the medicinal 
 
22 
Regulatory Mechanism (Total: 22) 
Accountability (6) 
Reporting model (4) 





products. Risk evaluation (3) 
Evaluation of products (3) 
Responsibility (2) 
 
 
